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Abstract. 
In the late 1980's it became apparent that misoprostol, a prostaglandin E1 
analogue tablet marketed for gastric ulcer care, could be used to stimulate 
contractions of a pregnant woman's uterus. The manufacturing company 
distanced themselves from any research or use of misoprostol during pregnancy. 
It therefore entered clinical use in a haphazard and uncontrolled way. 
The 40 papers which constitute the scientific basis of this thesis document a 
research program over the last 15 years which has focused on the obstetric use of 
misoprostol. These include a series of studies to determine the effectiveness and 
appropriate dosage and route of administration in two clinical settings: labour 
induction; and the prevention and treatment of haemorrhage after childbirth. The 
main methodology has been randomized clinical trials, and systematic reviews of 
randomized trials, with an emphasis on safety. 
In the case of labour induction, use of misoprostol even in relatively small dosages 
from time to time resulted in excessive contractions of the uterus, causing 
asphyxiation of the baby or rupture of the mother's uterus. A limiting factor was 
the lack of a tablet with sufficiently small dosage for safe use. The author 
developed a novel method of administration called 'titrated oral misoprostol 
solution' which allowed accurate administration of very small dosages. The 
papers document a series of randomized trials and systematic reviews showing 
that only in extremely small dosages was the safety of misoprostol similar to that 
of alternative prostaglandins registered for use for labour induction. The 'titrated 
oral misoprostol solution' method is now widely used internationally. 
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The papers also document development of a new methodology for organizing the 
systematic review of multiple interventions such as for labour induction, using a 
generic protocol for a series of reviews, and organizing the comparisons covered 
by each review by means of a hierarchical listing of the numerous interventions 
studied. 
Regarding the use of misoprostol after childbirth, the papers document the first 
randomized trials to be published using misoprostol for the prevention of 
postpartum haemorrhage, and also the first for the treatment of postpartum 
haemorrhage. Evaluation of the relative benefits and risks of misoprostol, based 
on randomized trials and systematic reviews, led to recommendations for a lower 
dosage than that recommended by the majority of workers in the field. 
Another original line of thought which the papers document, is the concept that 
whereas misoprostol reduces blood loss after childbirth, which is conventionally 
accepted as a proxy for a reduction in maternal deaths, effects on other organ 
systems might in fact increase the risk of death when used in excessive dosages. 
The research presented documents that 11 deaths have been recorded in women 
receiving misoprostol 600 micrograms or more in randomized trials, compared 
with 4 deaths in women receiving placebo or other uterotonics. 
The thesis argues that the data presented in the papers is sufficiently compelling 
to justify limitation of the misoprostol dosage used after childbirth to 400 
micrograms. 
The thesis narrative supplements the strictly quantitative methodology of the 
submitted papers with discussions ranging from the thought processes, 
associations and serendipity which generate innovation, to political and advocacy 
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issues which influence the global research agenda and the interpretation and 
implementation of research findings. 
The unifying theme of the thesis is the often underestimated potential for medical 
interventions to do more harm than good, because of the natural tendency of 
researchers and practitioners to give more attention to beneficial than to potential 
harmful effects of what they do. 
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1 Introduction 
After more than 30 years of confining myself to objective scientific writing 
(including the 40 papers which constitute the scientific basis of this DSc 
submission), I have decided to write this commentary from a personal, narrative 
and philosophical perspective. My reason is to add a dimension to the work which 
may provide insight into the relationship between personality and scientific 
discovery, and the often quirky and apparently unconnected chains of ideas which 
lead to innovation. It may serve to illustrate how working at the clinical coalface, 
particularly in an under-resourced setting, may expose one to experiences and 
predicaments which generate innovative ideas. I will also explore ways in which 
our human instincts, beliefs and natures may influence our scientific judgement, 
and the extent to which personal perspectives colour the global scientific debate. 
Two listings of references are used in the text of this thesis. Numbers in brackets 
e.g.(12) refer to one of the 40 attached publications submitted as the scientific 
basis for the DSc degree (these are listed in sections in the thesis in which they 
first appear, boxed, with a brief synopsis where needed). References in the 
Harvard Style e.g. (Coutsoudis, Coovadia & Wilfert, 2008) are references to 
support a concept in the thesis. These are listed in the reference list at the end of 
the thesis. 
A defining characteristic of my clinical and research endeavours has been an 
intuitive focus on the potential of health care to have unexpected and often 
unidentifiable harmful effects. This makes me something of an outlier in the health 
profession, which is characterised by a greater sense of confidence in our 
collective effectiveness than is my nature. 
Where did this scepticism originate? 
An early experience which impressed on me the potential for the medical 
environment itself to have adverse effects occurred in 1977 when my wife Carol 
and I worked as Medical officers at Holy Cross Hospital in Eastern Pondoland in 
the so-called independent Transkei. One day a young woman gave birth to her 
first child at the hospital. A few days after birth the apparently healthy baby died. 
It turned out that the mother had never fed the baby. When asked why not, she 
explained that no-one had said she may feed the baby. This tragic event 
illustrates the extreme degree of disempowerment patients, particularly those from 
already disempowered backgrounds, experience in a clinical setting, and how 
dangerous this may be. In hospitals, patients become isolated from their families 
and dependent on hospital staff, who mayor may not have the time or the insight 
to attend to their needs. Those who are not by nature assertive or by position in 
society influential are at greatest risk. An objective observer will identify many bad 
outcomes in our hospitals which would not have occurred had the victim been at 
home in the care of their family. 
A second concern is the possibility of direct adverse effects of medical 
interventions, most of which are and will remain, unknown. A corollary of the 
acceptance of this concept is that no treatment, however apparently safe, should 
be used unless there is robust evidence that it is effective. Then at least there is 
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the possibility that beneficial effects will outweigh harms. This principle is central 
to the work outlined in this commentary. 
One way in which our collective optimism and enthusiasm for medical 
interventions may endanger patients is by the selective use of scientific evidence. 
The first level at which this occurs is reliance on 'evidence' from observation of the 
effects of a medicine or other intervention. Most medical conditions improve over 
time. In many cases, improvement is promoted further by interactions such as 
care from an interested professional and the patient's belief that something 
positive is being done. Our view of the effectiveness of what we do is thus 
inherently biased by spontaneous recovery and effects of interactions over and 
above the medication. 
The best method we have available to reduce this bias, is by means of the double 
blind, randomized clinical trial. Patients who stand to benefit from the purported 
cure are assigned in a random sequence to receive the medication or an identical-
looking bland substance ('placebo'), in such a way that neither the patients nor the 
scientists know who received the placebo and who received the real thing. The 
outcomes in the two groups are compared, and if the treatment group do 
significantly better, there is some level of certainty that the treatment is effective. 
Even this approach is subject to bias. Because we are dealing with variable 
responses and measurements, every trial is an approximation of the true result, 
with some degree of over- or underestimation. Thus if an intervention is 
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ineffective and enough trials are carried out, the overall balance of results will 
show no effect, but some trials will by chance show 'evidence' of a benefit. 
Human optimism is such that practitioners tend to choose the most optimistic trials 
on which to base their practice. 
From the late 1970's onwards, lain Chalmers, Murray Enkin, Adrian Grant, Marc 
Keirse and others began work on the Herculean task of putting into practice Archie 
Cochrane's recommendation that we systematically summarise the results of all 
known clinical trials to get to the best possible evidence of effects of interventions. 
Mark Starr provided the software to synthesize the results of multiple similar trials 
(meta-analysis ). 
Given my predisposition to avoiding harm from ineffective medicines, I needed no 
convincing about the value of this approach, and in 1983 joined what was then a 
minority view that evidence from systematic review of randomized trials should 
trump our clinical observations. 
In general, the reaction to this approach from clinicians accustomed to unfettered 
use of their methods of personal choice was astoundingly negative, and at times, 
vicious. Thirty years on, there is widespread acknowledgement of the value of this 
approach and lain Chalmers' vision of a worldwide collaboration of contributors 
from all walks of life has taken form as the Cochrane Collaboration. 
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Systematic reviews cannot entirely eliminate our tendency to over-estimate the 
effectiveness of our medical treatments. Given the fact that all trials will have 
some error in one or other direction, our human preference for good news dictates 
that scientists whose results err on the optimistic side are more likely to persist 
with the research and have it published, creating an inherent 'publication bias' in 
the results available to us in the medical literature. 
Systematic reviews are the best we have, and we can improve their value by 
acknowledging their propensity to over-estimating effectiveness. 
1.1 Interlude 
On Monday 25 July, 2011, I arrived in Washington on the invitation of Mario 
Merialdi to participate in a WHO application for the USAID and partners 'Saving 
lives at birth' Grand Challenge for innovations finalists' meeting. It was an eventful 
2 days. I met Jorges Odon, the Argentinian inventor of the device which had been 
entered in the competition, and Javier Schwartzman who had initiated clinical 
tests. The device was an elegant two layered plastic sleeve for assisting the birth 
of a baby. 
In the lobby of the Fairfax Hotel, I was approached by Dr M A Quaiyum who told 
me that the government of Bangladesh in their 5 year health plan had approved to 
include misoprostol in the birth pack issued to all pregnant women in the country, 
to be taken after the birth. Based on my advice, they had chosen a dosage of 400 
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micrograms. The significant of this fleeting encounter will become apparent as we 
unravel the story of the obstetric use of misoprostol: innovations, evidence, 
controversy and global health perspectives. 
1.2 Misoprostol 
1.Hofmeyr GJ, Milos D, Nikodem ve, de Jager M. Limb reduction anomaly after 
failed misoprostol abortion. S Afr Med J. 1998; 88: 566-567 
One day a great novel will be written about misoprostol. The story has all the 
elements of compelling literature. It is a story of human and scientific endeavour, 
of women's quest for rights, of political expediency, hidden agendas and vested 
interests, of conflicting philosophies and beliefs; but most of all, it is a story of life 
and death. 
It is remarkable how long it can take the medical profession to cotton on to the 
blindingly obvious. This may be a function of our training. Often new ideas come 
from outside the health profession. Jorges Odon, the inventor of the Odon device 
to assist birth whom I referred to in the interlude above, is a car mechanic. 
Prostaglandins are naturally-occurring hormones which have ubiquitous effects on 
the human body. These include smooth muscle contractility and thus the flow of 
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blood through blood vessels, inflammatory processes, and keeping open the 
ductus arteriosis, the shunt between pulmonary and systemic circulations which 
allows unborn babies to survive until the pulmonary circulation opens up after 
birth. They have an important role in human labour and birth, by softening the 
uterine cervix and stimulating uterine contractions. 
Synthetic prostaglandins have been available for many years, and have been 
used for inducing labour, and for treating haemorrhage after childbirth. However, 
they could not be administered by mouth, and were too expensive for use in state 
services in low-income countries. 
Misoprostol is a unique prostaglandin analogue which can be administered by 
mouth and was developed, registered and marketed for the treatment of stomach 
ulceration caused by anti-prostaglandin (anti-inflammatory) medicines. 
References to misoprostol appear in the medical literature from 1981, and another 
synthetic prostaglandin E1 analogue was reported to be effective in inducing 
abortion in 1980 (Nakano et ai, 1980). The misoprostol package insert included a 
warning that it should not be taken during pregnancy as it may cause abortion. 
The number of years that this apparently obvious potential remained unexploited 
by the medical profession is astounding. The first reference to the use of 
misoprostol in pregnancy that I have found in the medical literature is a 1987 
paper documenting abortion as a side-effect of misoprostol (Rabe et ai, 1987). It 
is said that the first medical use of misoprostol in pregnancy was not by the 
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medical profession, but by women in Brazil who took the warning in the package 
insert seriously. 
The news spread like wildfire. At last health workers (and the public) in low-
income countries had their hands on an affordable medicine which gave them 
control over the initiation of labour. The sense of excitement and power was 
intoxicating. When one considers the mega-sums of advertising funds usually 
spent to launch a new product, that fact that the use of misoprostol spread 
exponentially (in spite of active discouragement from the manufacturers) is a 
measure of the avidity of health workers and women for such a product. 
The manufacturer and patent holder publicly distanced themselves from the use 
of, or research into the use of misoprostol during pregnancy. There were even 
rumours that the medicine might be taken off the market. I remember discussions 
with colleagues about stockpiling misoprostol in deep freezers against such an 
eventuality. Such was our enthusiasm to have and retain access to this product. 
This was a very dangerous situation. Across the globe, health workers and the 
public were experimenting with a drug for indications for which there were no 
guidelines regarding dosage or safety, because it had not gone through the 
normal regulatory process which includes strict and systematic scientific testing for 
effectiveness, safety and appropriate dosage. 
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As it turned out, use of misoprostol to terminate early pregnancy was extremely 
safe across a wide range of doses, up to 800 micrograms by mouth or vaginally 
(though failed abortion occasionally resulted in the birth of babies with missing 
limbs) (1). Use of very much smaller dosages to induce labour in late pregnancy 
sometimes produced disastrous results. 
1.3 Misoprostol for inducing labour 
2. Fawcus S, Mbombo N, Hofmeyr GJ. Trends in maternal deaths from Obstetric 
Haemorrhage in South Africa 2008 - 2010. Obstetrics and Gynaecology Forum 
2012:9-17 
Tablets are in general manufactured with an amount of active ingredient to provide 
the correct adult dose with one or two tablets. Misoprostol was marketed as 200 
microgram (mcg) tablets. Health workers started using one (or two) tablets by 
various routes to induce labour, and they worked wonderfully well. However, as 
with other prostaglandin preparations, the sensitivity of women's uteri in late 
pregnancy to misoprostol is exceptionally variable. Some women would not 
respond at all. Most would respond with good results, but every now and then, this 
dose would work too well, and the woman's uterus would contract with such force 
that it would burst, or rupture, and one of three things would happen: the baby 
might be born precipitously, and the bleeding from the rent in the uterus might be 
little enough to go undiagnosed, and the woman recover uneventfully; or the baby 
might be expelled from the torn uterus into the mother's abdominal cavity, and its 
lifeless body be retrieved by an abdominal operation; or the mother might die from 
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haemorrhage with or without the baby being born, and with or without anyone 
realising that the uterus had ruptured. 
Since 1998 South Africa has had a national system of confidential enquiries into 
maternal deaths of which we can be proud, thanks to the dedicated work of a 
team led by Prof Jack Moodley. Between the first report for 1998 and the second 
report for 1999 to 2001, there were only two causes of maternal death which 
increased significantly: infections (mainly HIV), and ruptured uterus. Though 
misoprostol was not always documented as a contributory cause, there is little 
doubt it was responsible for more cases than were recorded, for reasons which 
will appear below. 
The tragedy of this situation is that, had the use of misoprostol for labour induction 
followed the normal course of drug development, testing and marketing, the 
number of women with ruptured uterus would have been limited to one or two 
centres where the drug was being tested, and a safe dose would have been found 
before the drug became generally available, and supplied together with advice on 
the appropriate dosage. 
Instead, the drug was 'tested' unofficially by countless individual health workers 
worldwide, and the lesson of the risk of uterine rupture was learned over and over 
to the cost of countless women. Despite recent concerted efforts by global 
organizations to distribute guidelines for the safe use of misoprostol, this lesson 
continues to be repeated to this day, because the dosage information is not part of 
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the drug packaging. Advice on dosage distributed by global organizations is 
unpersuasive to doctors who have used their own preferred dosage for years very 
successfully, and without any identified accidents. 
One incident impressed on me the risk of uterine rupture even with a very small 
dose of misoprostol. Some years ago, when we were still using misoprostol 
administered by the vaginal route for labour induction, I was passing a young 
woman in the labour ward who was lying absolutely quietly, impassive and 
uncomplaining. I was about to pass by when I noticed a bead of perspiration on 
her forehead and a look in her eye which prompted me to ask her if she was 
alright. She said she was in excruciating pain. I examined her abdomen which 
was tender, and felt the baby lying outside the uterus, with no audible heartbeat. 
At operation we retrieved her stillborn baby and confirmed a rupture extending the 
whole length of one side of her uterus. She had received only one dose of one 
eighth of a misoprostol tablet vaginally. I shudder to think how many times this 
has happened worldwide, with the use of much larger doses over many years. 
I must hasten to reassure colleagues who may be shocked at my apparent use of 
'anecdotal' reporting (the bane of my scientific career), that the irony is intentional. 
This incident and those I will report below are very emotive, but should not be 
confused with evidence. They are selected cases with bad outcomes. They don't 
tell us how many good outcomes there were, nor whether the bad outcomes would 
have been more or less frequent had another medication been used or no 
11 
medication at all. Penicillin and immunizations cause many deaths due to 
hypersensitivity, but we assume that the deaths prevented outnumber those 
caused. 
On another occasion in our hospital service, a 25-year-old mother with two 
previous normal births had labour induced with low-dose misoprostol. After the 
birth of a live baby she developed postpartum haemorrhage, and died during 
resuscitation attempts. Had a post-mortem examination not been performed, the 
diagnosis of ruptured uterus would have been missed. 
We stopped using misoprostol administered by the vaginal route for labour 
induction, but even low dose oral administration is not without risk. One evening 
recently I was called to the labour ward. A young women with two previous 
pregnancy losses had had labour induced with low-dose misoprostol. All had 
seemed fine when suddenly the baby's heartbeat had disappeared and her 
abdomen had become tense and tender. With these typical signs, placental 
abruption (bleeding between the placenta and the wall of the uterus) had been 
diagnosed. I was called in to confirm with ultrasound that the baby's heartbeat 
was indeed no longer present, and was distracted from further clinical examination 
by the need to console the distraught parents. I accepted the diagnosis of 
placental abruption, and expected rapid progress to delivery to occur. I was 
phoned in the early hours of the morning by the medical officer who reported that 
the baby was not yet born. In that instant I realised that we had missed the 
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diagnosis of ruptured uterus. The operative findings were very similar to the case 
above, a torn uterus and the dead baby lying among the abdominal organs. 
I mention these cases as they are very unusual with such a low dose of 
misoprostol - the vast majority of cases of uterine rupture are due to excessive 
dosages. But such is the variability in uterine sensitivity to stimulants that in 
exceptional cases even a very low dose may be too much. 
The most recent confidential enquiry into maternal deaths in South Africa (2008 to 
2010) again emphasizes the abnormally high rate of rupture of unscarred uteri (2). 
The paper cited was largely the work of Sue Fawcus. The statistically significant 
increased incidence of ruptured uterus referred to above in 1999 to 2001 
compared with the previous report, has been sustained. The deaths from 
haemorrhage in institutions numbered 25 per 100000 live births (slightly up from 
19 in the previous 3 years). Of 688 such deaths, 108 were identified as due to 
ruptured uterus, including 61 women with no previous caesarean section. This 
may be an underestimate as post-mortem examinations were seldom undertaken 
and in 128 deaths due to haemorrhage no cause was reported. Inappropriate use 
of misoprostol, including doses as high as 400 mcg, was highlighted as a 
contributory factor to these alarmingly high figures. In one example cited in the 
report, a 40-year-old mother of 4 carrying a dead baby received misoprostol 100 
mcg vaginally at 17hOO. At 02hOO she was found dead, with a ruptured uterus. 
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Recently (during 2012) a young woman was referred to us from a peripheral 
hospital. She had developed jaundice and her baby had died. Labour had been 
induced with misoprostol 200mcg vaginally. She delivered very quickly, followed 
by a postpartum haemorrhage. Shortly after reaching our hospital she died. 
Postmortem examination confirmed that the cause for the haemorrhage was a torn 
uterine cervix. A recent randomized trial has confirmed that the risk of postpartum 
complications such as cervical and vaginal tears is more common when labour is 
induced with 50 than with 25mcg misoprostol vaginally (Loto et ai, 2012). 
The reason for the continued use of these high doses in women with an unborn 
dead baby is tragically simple. The most common adverse effect of misoprostol is 
excessive uterine contractions causing asphyxiation of the baby. When the baby 
is dead, health workers assume that it is no longer necessary to use a small 
dosage. 
The unusually high frequency of uterine ruptures continues unabated. 
1.4 Concealing the evidence 
The second factor which makes this situation even more perilous for women 
relates to the 'off-label' use of medication, the use for an indication not covered by 
the conditions for which it has been licensed. This is a common and necessary 
practice. Many life-saving drugs are used for conditions for which they have not 
been registered. The catch is that in the event of an adverse event, the 
responsibility lies with the practitioner rather than with the supplier. Health 
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workers sometimes use misoprostol for labour induction without recording this in 
the patient record, in order to avoid possible legal repercussions. Over the years, 
I and my colleagues have encountered many women whose labour has been 
induced with misoprostol without any record in their notes, and sometimes without 
their knowledge. All we find are the characteristic hexagonal white tablets which 
have been inserted during a vaginal examination. 
On one occasion, a 25-year-old mother with one previous caesarean section, 
carrying a dead baby at 24 weeks of pregnancy, came to our hospital service with 
abdominal pain. We found 6 misoprostol tablets (1200 mcg) in her vagina, which 
she said a private doctor had inserted. She rapidly gave birth to an 840 gram 
stillborn baby, and fortunately was well thereafter. 
One unusual case of a different nature that I encountered was of a young woman 
in early pregnancy who presented with a threatening miscarriage. On examination 
I found several misoprostol tablets in her vagina of which she had been unaware. 
It turned out that her estranged boyfriend had feigned reconciliation, and during 
sexual intercourse had surreptitiously inserted the misoprostol to induce an 
abortion. 
In passing, the relatively low cost of misoprostol for labour induction is an 
aberration related to the fact that it was not marketed for this purpose. Had it been 
marketed for labour induction, it would probably have been marketed at a price 
similar to other labour induction prostaglandins, because each patient uses only a 
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small amount. Because it was marketed for long-term use for anti-prostaglandin-
induced gastric ulceration, it had to be priced at a much lower level. I think that is 
how The Market works. (To be fair, the development costs to the company and the 
risk costs for use in pregnancy would have been higher as well). 
This detailed discussion of the unusual circumstances surrounding the introduction 
of misoprostol to obstetric practice has been necessary to introduce the first theme 
of this dissertation: Labour induction with misoprostol: finding the right dose and 
route. 
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2. Labour induction with misoprostol: finding the right dose and route 
3. Hofmeyr GJ. Misoprostol in obstetrics and gynaecology - unregistered, 
dangerous and essential. S Afr Med J 1998; 88: 535-536 
Editorial outlining the dangers of using misoprostol for labour induction prior to 
establishment of safe regimens, as well as its use for postpartum haemorrhage prior 
to establishing evidence of effectiveness and safety. 
Once the potential of misoprostol for labour induction was recognised, the field 
became something of a gold rush. The availability of an inexpensive and powerful 
prostaglandin was intoxicating to researchers and practitioners alike. In a 1998 
editorial I cautioned against the use of misoprostol in clinical practice prior to the 
establishment of safe regimens (3). 
The vast majority of reports followed the paradigm which had been successful for 
other prostaglandin products: a fixed, infrequent dose administered vaginally. 
The concept of administering the drug close to the cervix with the expectation of a 
direct effect on cervical ripening was intuitively an attractive one. 
A minority of researchers chose the oral route - at either 4- or 6-hourly intervals. 
2.1 A new paradigm 
4. Hofmeyr GJ, Matonhodze BB, Alfirevic Z, Campbell E, de Jager M, Nikodem 
C. Titrated oral misoprostol solution--a new method of labour induction. S Afr 
Med J. 2000; 91: 775-6. 
We pi/ot tested our novel, low-dose method in 25 women with various indications 
for induction of labour. Eighteen women (72%) delivered vaginally within 32 
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hours of induction and two women developed uterine hyperstimulation. The 
caesarean section rate was 20%. 
I chose to approach the problem from a paradigm more closely aligned to that of 
oxytocin, in which a continuous intravenous infusion is used, starting at a low dose 
and titrating against the woman's individual response. Misoprostol is not available 
in intravenous form, but given its rapid absorption orally and relatively short half-
life, I introduced the concept of using small, frequent (2-hourly) oral doses, and 
titrating (increasing or reducing) the dose according to the uterine contraction and 
labour progress response. 
A major barrier to administering a small dose was that misoprostol was marketed 
as a 200 microgram tablet. It was common practice to break the tablet into 4 or 8 
fragments, but it was impossible to be sure how much of the active ingredient was 
in the fragment administered. 
I developed the idea of dissolving the 200microgram tablet in 200ml of water, 
shaking well, and measuring out an appropriate volume of the solution (eg 25ml = 
25 micrograms), administered orally. I called this approach "titrated oral 
misoprostol solution", and it has stood the test of time, being used in many 
countries today (4). 
2.2 Testing titrated oral misoprostol solution 
5. Hofmeyr GJ, Alfirevic Z, Matonhodze B, Brocklehurst P, Campbell E, Nikodem 
VC. Titrated oral misoprostol solution for induction of labour: a multi-centre, 
randomised trial. Br J Obstet Gynaecol. 2001; 108: 952-959. 
Women due for labour induction were randomly allocated: 346 to titrated oral 
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misoprostol solution and 349 to vaginal dinoprostone. There were no significant 
differences in substantive outcomes. Vaginal delivery within 24 hours was not 
achieved in 38% of women in the oral misoprostol group and 36% in the vaginal 
dinoprostone group (RR 1.08; 95% CI 0.89-1.31). The caesarean section rates 
were 16% and 20%, respectively (RR 0.80; 95% CI 0.58-1.11). Hyperstimulation 
with fetal heart rate changes occurred in 4% and 3% respectively (RR 1.32, 95% 
CI 0.59-2.98). There were no differences in neonatal outcome between the two 
groups. This new approach to oral misoprostol administration was successful in 
minimising the risk of uterine hyperstimulation, which has been a feature of 
misoprostol use for induction of labour. 
The annual 'Priorities in Perinatal Care in Southern Africa' conferences were 
initiated by Alan Rothberg in the 1980's, and are a unique forum for interaction 
between obstetricians, midwives, neonatologists and neonatal nurses as well as 
other professionals with an interest in the wellbeing of childbearing women and 
their babies in poor countries. At one such meeting in the Drakensberg, I 
discussed with Zarko Alfirevic setting up a multicentre trial between Coronation 
Hospital and Liverpool Womens' Hospital. For our initial work I had chosen a 
dosage of 20 micrograms, because it could easily be scaled down to 10 or even 5 
micrograms. Zarko argued that 25 micrograms would 'sell' better as it fitted with 
the 200/100/50/25 microgram dosages which were familiar to most practitioners. 
We agreed on his dosage, and I'm sure he was right. The trial which followed 
confirmed our earlier work, and the effectiveness of the titrated oral misoprostol 
solution approach (5). 
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2.3 Order from chaos 
6. Hofmeyr GJ, Alfirevic Z, Kelly T, Kavanagh J, Thomas J, Brocklehurst P, 
Neilson JP. Methods for cervical ripening and labour induction in late pregnancy: 
generic protocol (Protocol for a Cochrane Review). In: The Cochrane Library, 
2000. Oxford: Update Software 
The first generic protocol in the Cochrane Library - outlining a systematic 
strategy for reviewing data from multiple trials of labour induction, and serving as 
a template for the series of reviews. 
Trials of misoprostol for labour induction proliferated at a remarkable rate. How 
were we to make sense of a multitude of trial results reported globally, using 
various dosages, different time intervals, different routes of administration and 
different comparisons? 
As mentioned in the introduction, lain Chalmers, Mark Starr and colleagues had 
given us the tools to synthesize the results of multiple similar randomized trials by 
meta-analysis. In the field of labour induction we were dealing with not only the 
multiplicity of variables involving misoprostol, but more than 20 methods of labour 
induction in a variety of clinical situations. A system was needed to give order to 
the task of summarising this complex mass of information. 
I spent some time with Zarko Alfirevic in Liverpool to develop a strategy, and came 
up with two new concepts in the field of systematic reviews. 
The first was what we called a 'generic' protocol which served as a template for a 
series of reviews of different methods of labour induction using the same methods 
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and outcome measures. This would provide uniformity, and greatly speed up the 
process of synthesizing the huge volume of experimental work (6). 
Because any of the multiple methods of labour induction might be compared in a 
randomized trial with any other, the comparison of method A with method B would 
be duplicated in the reviews both of method A and of method B. To eliminate this 
duplication, we came up with a simple system of ranking all the methods from 
number 1 to number 25, and for each individual review comparing the particular 
method only with methods above it on the list. We allocated placebo number 1 so 
that all reviews would include a placebo comparison, and then ranked the 
methods roughly from the most conventional and well-established to the least 
conventional and recent. Thus in general, reviews of newer methods would 
include comparisons with more established 'gold standards'. 
These innovations have proved very useful in bringing order to what would have 
been a chaotic multiplicity of reviews of labour induction, and have been adopted 
for other series of reviews involving multiple methods. The huge workload of 
completing and updating all these reviews was shared between a team of 
collaborators, with particular support from the UK National Institute for Clinical 
Excellence (NICE). 
2.4 Systematic reviews and dosage 
7. Hofmeyr GJ, Gulmezoglu AM, Pileggi C. Vaginal misoprostol for cervical 
ripening and induction of labour. Cochrane Database Syst Rev. 2010; 
10:CD000941 
First published in 1998 and updated regularly since then. 
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8. Hofmeyr GJ, Gulmezoglu AM, Alfirevic Z. Misoprostol for induction of labour: 
a systematic review.Br J Obstet Gynaecol. 1999;106:798-803. 
9. Hofmeyr GJ. Induction of labour with misoprostol. Curr Opin Obstet Gynecol. 
2001; 13: 577-81 
10. Hofmeyr GJ, Gulmezoglu AM. 251-1g misoprostol is less effective than 50 I-Ig 
for induction of labour, but has lower risks - meta-analysis (commentary). 
Evidence-based Obstetrics and Gynaecology 2002; 4: 211-212. 
Commentary on a North American meta-analysis showing greater safety with the 
lower dose. 
11. Hofmeyr GJ. Induction of labour with an unfavourable cervix. Best Practice 
& Research Clinical Obstetrics & Gynaecology 2003; 17: 777-794 
7 - 11: Series of systematic reviews progressively updating the world literature 
to provide up to date guidance for clinicians and policy-makers. 
The value of Cochrane systematic reviews in general, and of our methodical 
approach to reviews of labour induction in particular, is well illustrated by the 
efficiency with which continuously updated systematic reviews were able to bring 
together results from a torrent of uncoordinated trials worldwide and produce 
rational guidance within a short time-frame (7-11). 
However, the value of systematic reviews was not universally acknowledged. 
The question of dosage became something of an international football. 
On 7-8 May 2001 a global meeting was called at the Population Council 
headquarters in New York entitled Misoprostol: An emerging technology for 
women's health. At the time, the American College of Obstetricians and 
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Gynecologists recommended a dose of 50 micrograms of misoprostol vaginally, 4-
hourly, to induce labour. Metin Gulmezoglu and I were invited to present the 
results of the Cochrane review which showed that 25 micrograms was a safer and 
almost as effective dose. Some North American delegates were totally dismissive 
of our data, arguing that their personal experience of large numbers of labour 
inductions with the 50 mcg dose convinced them of the safety of that dose. The 
interactions highlighted the tensions which exist between an evidence-based 
approach and that guided by clinical experience. A contemporary review 
concluded that "there is strong and consistent evidence to support the use of 
misoprostol for induction in the third trimester" (Goldberg Greenberg & Darney, 
2001). We left New York frustrated, but fairly certain that sooner or later 
proponents of the 50mcg dose would recognise the greater safety of the smaller 
dose and the ACOG would amend the guidelines, which has happened (ACOG, 
2009). 
2.5 Which route for labour induction? 
12. Matonhodze BB, Hofmeyr GJ, Levin J. Labour induction at term--a 
randomised trial comparing Foley catheter plus titrated oral misoprostol solution, 
titrated oral misoprostol solution alone, and dinoprostone. S Afr Med J. 2003; 93: 
375-379. 
Women due for labour induction were randomly allocated to extra-amniotic Foley 
catheter followed by titrated oral misoprostol solution, titrated oral misoprostol 
solution alone, or vaginal dinoprostone. Misoprostol was dissolved in water and 
20 - 40 g was given 2-hourly. In the Foley catheter group, misoprostol was 
required in all but 1 case. Failure to deliver vaginally within 24 hours was similar 
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for the three groups (79/174 v. 70/176 v. 70/176 respectively). Labour 
augmentation, caesarean section and instrumental delivery were used somewhat 
more frequently in the Foley/misoprostol group than in the misoprostol alone 
group, but these differences were not statistically significant. More analgesia was 
used in the Foley catheterlmisoprostol group than in the misoprostol group 
(64/172 v. 46/175). Side effects and neonatal complications were similar for the 
three groups. Use of extra-amniotic Foley catheter placement showed no 
measurable benefits over the use of oral misoprostol alone, or vaginal 
din oproston e . 
The next counter-intuitive evidence which our system of ongoing systematic 
review produced was the fact that although clinicians intuitively preferred the 
vaginal route of administration, and the great majority of trials investigated the 
vaginal route, a steady trickle of trials using the oral route, including ours, over 
time produced cumulative evidence to show that the oral route was as effective as 
the vaginal route, with less uterine hyperstimulation. 
There was yet another turn of the wheel which emanated from the systematic 
review process, and brought us full circle in our search for a safe, affordable 
method of labour induction. Before prostaglandins were available, we had used a 
balloon catheter (such as a Foley catheter) inserted through the uterine cervix and 
held under tension, to induce labour in the presence of an unfavourable cervix. 
With the advent of expensive vaginal prostaglandin preparations, actively 
promoted by the manufacturers, these were assumed to be a more sophisticated 
and superior option, and the balloon catheter assumed the position of a second 
best approach when prostaglandins were unaffordable. With the advent of 
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misoprostol as an affordable prostaglandin, the balloon catheter was considered 
more or less obsolete. I had encouraged one of the PhD students I supervised, Dr 
Baron Matonhoze, to include the Foley catheter as one of three arms in a 
randomized trial of labour induction, and the results had in fact been disappointing 
(12). In retrospect, it may be that we did not apply sufficient traction to the Foley 
catheter. 
However, the occasional trial of the balloon catheter continued to appear, and in 
time the relevant Cochrane systematic review accumulated sufficient evidence to 
show that the balloon catheter was in fact safer than either purpose-designed 
prostaglandin preparations or misoprostol. 
What can account for the fact that the prostaglandin preparations (mainly 
dinoprostone) developed for labour induction comprehensively replaced an 
existing method (the balloon catheter) which subsequently turned out to be the 
safer method? The answer is simply: advertising. Pharmaceutical companies 
have an extremely important role to play in healthcare, as they have the capacity 
to develop and distribute new drugs and devices which contribute to on-going 
improvements in health. However, they are businesses, not charitable institutions. 
They would not spend huge amounts of their hard-earned profits on advertising if 
they did not have pretty solid evidence that advertising had a major effect on the 
use of drugs by doctors. Thus prostaglandins replaced the balloon catheter 
because they were actively promoted by their manufacturers, whereas the balloon 
catheter was not promoted for labour induction at all, as it was marketed for 
entirely different purposes. There is also the greater simplicity and comfort of the 
gel preparation, and the innate preference of professionals for a pharmacological 
medication over a simple, mechanical method. The uptake of misoprostol was 
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unusual in that it was driven by the enthusiasm of health providers, lobby groups 
and women rather than advertising efforts of the manufacturer. 
The method of titrated oral misoprostol solution for labour induction that I devised 
in the 1990's has been incorporated into the South African National Essential 
Drugs List Committee guidelines, and is used in many countries across the globe. 
With the evolving evidence from the systematic reviews we have adjusted our own 
practice to use the balloon catheter as a first line method of labour induction, 
reserving titrated oral misoprostol solution for cases where rapid induction is 
critical, and those where the balloon catheter method is unsuccessful. 
2.6 Misoprostol and meconium 
13. Mitri F, Hofmeyr G J & Van Gelderen C J. Meconium during labour: self-
medication and other associations. S. Afr. Med. J 1987; 71: 431-433. 
In an observational study we found a trend to increased use of 'isihlambezo' in 
women with meconium-stained amniotic fluid. 
14. Matonhodze BB, Katsoulis LC, Hofmeyr GJ. Labor induction and meconium: 
in vitro effects of oxytocin, dinoprostone and misoprostol on rat ileum relative to 
myometrium. J Perinat Med. 2002; 30: 405-10. 
The contractile activity of dinoprostone, misoprostol and oxytocin was tested on 
isolated rat uterus and ileum mounted in Tyrode's solution. Uterine contractions 
were stimulated by all three drugs, whereas ileal contractions were stimulated 
only by dinoprostone and misoprostol. 
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Our series of systematic reviews was also the first to identify robust evidence that 
use of misoprostol was associated with an increase in meconium staining of the 
amniotic fluid. One of the many marvellous features of the physiology of the 
unborn baby is that passage of meconium (stool) is normally suppressed until after 
the birth. Stool passage before birth can be a life-threatening complication as the 
meconium may be inhaled by the baby causing chemical inflammation of the lungs 
(meconium aspiration syndrome), which carries a high mortality. 
In the 1980's, we had been struck by the frequency of meconium staining of the 
amniotic fluid at Baragwanath Hospital. I encouraged one of our registrars, Dr 
Faouzi Mitri, to conduct an observational study to see whether there was a 
relationship between herbal and other remedies taken by women in Soweto, and 
meconium passage by the unborn baby. We found a significant association of 
meconium staining with ingestion of castor oil, and a trend to increased meconium 
passage with ishlambezo (13), a herbal remedy widely used in Southern Africa. 
We went on to show, with our colleagues from the pharmacology department, that 
isihlambezo contained plant alkaloids which cause contraction of both uterine and 
bowel smooth muscle (Katsoulis, Veale & Hofmeyr, 2000). Prior to this, it was 
thought that meconium passage was usually a baby's response to stress. We 
developed the hypothesis that in addition, meconium passage might be caused by 
smooth muscle stimulants crossing the placenta and directly stimulating the baby's 
bowel. This was of importance because it meant that meconium passage might 
not necessarily be an indication of distress, and interventions such as caesarean 
section might not always be appropriate. This did not mean that meconium could 
be ignored. Whatever the cause of the meconium passage, the risk of it being 
breathed in by the baby, particularly at the time of birth, remains. 
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In another facet of Dr Matonhodze's PhD work referred to previously, we repeated 
these in vitro studies, and found a similarity between misoprostol and ishlambezo: 
whereas oxytocin (the human hormone associated with uterine contractions in 
labour) stimulated rat uterine muscle but not bowel, misoprostol, like isihlambezo, 
stimulated both the uterus and the bowel (14). We put forward the hypothesis that 
misoprostol might cause meconium passage by crossing the placenta and directly 
stimulating the baby's bowel. 
Before closing this chapter, I would like to pay tribute to the optimism, tenacity and 
perseverance against all odds of the PhD student, Baron Matonhodze, to whose 
work I referred above. During the clinical work at Coronation Hospital and the 
laboratory work in the department of Pharmacology, he underwent major surgery 
and radiation therapy for cancer. In January 2001 he was due to come down to 
East London to complete the PhD write-up when he sustained a major head injury 
in a motor vehicle accident. Recovery took more than a year, but he persisted, 
and graduated in 2005. 
Our and others' evidence of the need to use very low dosages of misoprostol for 
labour induction has been widely acknowledged, but as illustrated above, the use 
of higher doses continues to inflate the maternal mortality rates in South Africa. 
The situation is certainly improving, but we need to reflect on whether the benefits 
of misoprostol used in appropriate dosage will ever outweigh the cumulative cost 
in loss of mothers' and babies' lives from over dosage? 
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2.7 Misoprostol and preterm birth 
One January, we noticed that our high-care nursery was more crowded than 
usual. One of our nurses remarked, as if it were a matter of common knowledge, 
that this was because the new school year was about to start, and schoolgirls 
would not be allowed to enrol if they were pregnant. 
In accordance with South African law we provide a free pregnancy termination 
service on request up to 13 weeks, and for medical or psycho-social reasons 
(including poverty), up to 20 weeks. This includes just about everyone. But not 
after 20 weeks. This is where entrepreneurs fill the gap. 
Our patients tell us that the way it works in East London is that one calls a 
cellphone number found on one of many posters which adorn the street poles in 
Oxford street, advertising 'safe, painless abortion'. One is met by the practitioner 
who provides several misoprostol tablets for about R800 (about 100 US dollars), a 
plastic bag to put the baby into when born, and a number to call for the bag to be 
collected and disposed of. No examination or estimation of the duration of the 
pregnancy takes place. 
Others simply sell misoprostol tablets as a business. One such businesswoman 
said in a newspaper interview that she buys 60 misoprostol tablets a week for 
R350 from pharmacy staff who steal them, and sells them at R200 for 4. The 
business model is nothing of not entrepreneurial. 
Occasionally women using these parallel services arrive at the hospital in 
apparently spontaneous preterm labour or having given birth to a small baby at 
home. Unknowingly, we do everything we can to reverse the process. We give 
medication to suppress the contractions of the uterus; we give steroids to mature 
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the baby's lungs; after the birth, we resuscitate the baby, admit him or her to our 
already overcrowded high care unit; administer surfactant, continuous positive 
airways pressure, and all the care our limited resources allow us to, in an attempt 
to save the baby's life. Many of the babies are very small indeed, and don't 
survive. They appear on our records as neonatal deaths from spontaneous 
preterm birth, and contribute to our ever diminishing chance of achieving the 
Millennium Development Goals' objective to reduce deaths of babies and children. 
Generally, fear of repercussions would prevent women from confiding in us that 
the preterm labour was not spontaneous, but now and then they do. 
To try to get an idea of how often this was happening, I asked Sibongile 
Mandondo, one of our registrars in training, to conduct an observational study. 
Over 6 months, she came to know of 18 women who had taken misoprostol to 
induce early labour. The dosages ranged from 400 to 1200mcg. The gestational 
ages ranged from 24 to 39 weeks. Eleven babies were born alive, and one 
survived. One baby remained unborn, the mother presenting because of fear that 
the baby may have been harmed by the failed attempt. One mother with previous 
caesarean section sustained a ruptured uterus which we repaired, and one 
developed shock from severe infection. 
This is likely to be the tip of the iceberg. 
I mention this issue not to be in any way judgemental, but to illustrate the 
complexity of providing care for women in an environment which precludes 
openness in our interactions, and of assessing the quality of perinatal care against 
an unmeasurable background of purposeful perinatal deaths. 
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3. Misoprostol after childbirth 
3.1 How do new ideas come about? 
It is remarkable, given the cumulative extent of global intelligence, how long it 
sometimes takes for new ideas to surface, which in retrospect appear obvious. It 
seems obvious now that the most stable way to pull a suitcase on wheels is on its 
side, to provide a wide wheelbase. For many years, wheels were placed at the 
bottom with the suitcase in the upright carrying position, with a wheelbase so 
narrow that the smallest bump would unbalance it. Before the advent of wheels 
on suitcases, suitcases had been carried in an upright position, and the first 
people who put wheels on suitcases worked within this entrenched paradigm. 
Who was the first person to think of tipping the case on its side to position the 
wheels more widely apart? And why did it take so long? 
My observation is that new ideas are often serendipitous, the results of apparently 
unrelated trains of thought, and often occur to someone outside the field of study 
(those in the field are too locked into the prevailing thought paradigms). 
For myself, when I am unable to solve a problem, I need to dissociate my thoughts 
from the conventional paradigm by going running. More often than not, after 
several kilometres when I seem to be thinking about nothing in particular, the 
solution will pop up for no apparent reason. 
Haemorrhage after childbirth (postpartum haemorrhage) is one of the main causes 
of maternal deaths, particularly in low-resource settings. For decades it has been 
known that drugs which cause contraction of the uterus (such as ergometrine, 
oxytocin and prostaglandins), reduce the bleeding. Today, the notion that 
misoprostol should be an ideal drug for preventing and treating postpartum 
31 
haemorrhage seems obvious, and it has become the focus of global efforts to 
reduce maternal deaths from postpartum haemorrhage in low-resource settings. 
Misoprostol has been known to be an orally active prostaglandin analogue for 
decades, and was reported to be a powerful stimulant of the pregnant uterus as 
early as 1988 ( Mariani Neto Delbin & do Val Junior, 1988). The thought of using 
misoprostol for preventing postpartum haemorrhage occurred to me only in 1995, 
and I can find no record or mention of its use for this purpose before this time. I 
first discussed the idea with colleagues from London at the 27th British Congress 
of Obstetrics and Gynaecology in Dublin in July 1995. The sequence of thought 
processes which gave rise to the idea are interesting to analyze. 
I have outlined above our work on the possible relationship between the use of the 
herbal remedy isihlambezo and passage of meconium by the unborn baby. By 
wrestling with the problem of how to discourage the use of isihlambezo during 
pregnancy without being disrespectful of a cultural practice, I came up with the 
idea of encouraging women to use isihlambezo after, rather than before the birth. 
This would avoid the risks to the baby, and the stimulant effect on uterine muscle 
might help to reduce postpartum haemorrhage. I think it was this train of thought 
which resurfaced years later as the idea to use misoprostol after childbirth. As 
discussed in the chapter on labour induction above, there are many similarities 
between isihlambezo and misoprostol. 
As is often the case, the idea of using misoprostol for preventing postpartum 
haemorrhage probably occurred to several people independently around the same 
time. The first publication I can find was a report of cases published in May 1996 
(el-Refaey, 1996). 
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3.2 The concept 
There are in our lives moments of intense emotion, positive or negative, which are 
burned in our consciousness and remain with us forever. I remember as if it were 
yesterday the sense of excitement when the thought first occurred to me that 
misoprostol might be the global answer to the scourge of postpartum 
haemorrhage. For someone who had committed years of work to seeking ways to 
reduce maternal deaths globally, it was like catching a glimpse of the Holy Grail. 
Misoprostol had all the qualities we had been searching for. It was inexpensive, a 
powerful stimulant of uterine muscle, and most importantly, whereas other uterine 
stimulants such as oxytocin or ergometrine were dependent on a health provider 
for administration by injection, it could be taken by mouth. Given the fact that a 
large proportion of women globally have no access to skilled attendance during 
childbirth, the potential to supply these tablets to women to take themselves after 
the birth of the baby opened a whole new paradigm for the elimination of 
unnecessary deaths from postpartum haemorrhage. 
3.3 The testing: a new route of administration 
15. Hofmeyr GJ, Nikodem ve, de Jager M, Gelbart BR. A randomised placebo 
controlled trial of oral misoprostol in the third stage of labour. Br J Obstet Gynaecol 
1998; 105: 971-975. 
Women in labour were randomly allocated to receive either misoprostol 400 mcg 
or placebo after the birth. A pilot study in 70 women using a novel route of 
administration, the buccal route, found no difference in haemorrhage. Thus for 
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the main trial, the oral route was used. Conventional oxytocics were given 
immediately if blood loss was thought to be more than usual. Measured blood 
loss> or = 1000 ml occurred in 151250 (6%) after misoprostol and 231250 (9%) 
after placebo (relative risk 0.65; 95% confidence interval 0.35-1.22). The 
difference may have been reduced by the greater use of conventional oxytocics 
in the placebo group, which was statistically significant for intravenous oxytocin 
infusion (2.8% vs 8.4%, relative risk 0.33, 95% confidence interval 0.14-0.77). 
Shivering was more common in the misoprostol group (19% vs 5%, relative risk 
3.69; 95% confidence interval 2.05-6.64). 
16. Hofmeyr GJ, GOlmezoglu AM. Misoprostol for the prevention and treatment 
of postpartum haemorrhage. Best Pract Res Clin Obstet Gynaecol. 2008; 22: 
1025-41. 
A review of pharmacokinetic, physiological and clinical research to determine the 
effectiveness and risks, and optimal dosage and routes of administration of 
misoprostol after childbirth. 
All that was needed was proof that misoprostol was effective for reducing 
postpartum haemorrhage in the clinical setting, which seemed a formality. The 
drug was in every way so perfect for the purpose. We set out to confirm 
effectiveness scientifically in the appropriate way: by conducting a double blind, 
placebo-controlled randomized clinical trial (15). After receiving ethical approval, 
we started counselling pregnant women about the trial, and to those who 
volunteered to participate we gave two tablets which might be misoprostol or 
placebo to take after birth. Because of the need for rapid action, we introduced a 
novel method of administering the misoprostol buccally, on the assumption that 
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absorption from the buccal/sublingual mucosa would be more rapid than from the 
stomach. To assess whether this novel method was effective we conducted a 
randomized pilot study of just 70 cases. We found no difference in the blood loss 
between misoprostol and placebo. So sure were we that misoprostol would be 
highly effective, that we assumed that the lack of effect was due to inadequate 
absorption from the buccal route, possibly due to lack of an acid environment to 
convert misoprostol to the acive metabolite, misoprostol acid, and we reverted to 
the oral route in our ongoing randomized trial. Ironically, our subsequent review of 
pharmacokinetic, physiological and clinical studies (16) showed excellent 
absorption from the buccal/sublingual route, and it has become a widely used 
method. 
Though we were the first to report use of this route of administration, we made the 
wrong inference because of our excessive enthusiasm for and belief in the 
effectiveness of misoprostol. The next report of the use of sublingual misoprostol 
following our 1998 publication was in November 2001 (Tang & Ho, 2001). 
3.4 The poor man's placebos 
Because the company marketing misoprostol had distanced themselves from any 
research on misoprostol during pregnancy (or even after pregnancy), we were 
unable to obtain identical placebos. We improvised a method in which misoprostol 
or placebo tablets of similar size but not identical in appearance were concealed in 
an opaque test tube. The woman was asked to open the tube and tip the tablets 
directly into her mouth without them being seen. This rather simplistic innovation, 
though clearly less reliable as a form of blinding, worked very well in practice. 
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3.5 Measuring blood loss 
Most previous trials of methods of preventing postpartum haemorrhage had used 
the traditional method of estimating blood loss after the birth. This is of course an 
extremely inaccurate method (often under-estimating by as much as 50%), and 
subject to considerable bias. We decided to measure the blood loss, and came 
up with a novel method of slipping a low-profile plastic 'fracture bedpan' (used by 
orthopaedic surgeons to slip under the buttocks of immobilised orthopaedic 
patients) under the woman's buttocks after the birth. It worked unexpectedly well. 
It was comfortable for the woman, very efficient at collecting all the blood loss, and 
the nursing staff were delighted not to be dealing with blood-soaked bed linen. 
3.6 The results 
17. Hofmeyr GJ, Nikodem ve, de Jager M, Drakely A. Side-effects of oral 
misoprostol in the third stage of labour: a randomised placebo-controlled trial. 
SAMJ 2001; 91: 432-435; S A J Obstet Gynaecol 2001; 7: 41-43. 
Women in labour were randomly allocated to receive either misoprostol 600 mcg 
or placebo orally after birth. Conventional oxytocics were given immediately if 
blood loss was thought to be more than usual. Misoprostol use was associated 
with more shivering (44% versus 11%, relative risk (RR) 4.03, 95% confidence 
irlterval (CI) 2.85 - 5.70) and pyrexia - 37.8°C (38% v. 6%, RR 6.23, CI3.89-
9.97). There was no difference in blood loss> 1 000 mI. Possible effects on blood 
loss may have been obscured by the lesser use of additional oxytocics in the 
misoprostol group (14% v. 18%, RR 0.78, CI 0.54 - 1.13). 
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We randomly compared misoprostol 400mcg after birth with placebo (15). The 
trial showed a trend to reduced haemorrhage with misoprostol, but nothing like the 
impressive effect we had expected. This was the first published randomized trial 
of oral misoprostol used in the third stage of labour, and also the first to prove an 
association of misoprostol with shivering. We realised then that we would need to 
balance the beneficial effects of misoprostol with possible adverse effects. 
We subsequently compared misoprostol 600 micrograms with placebo (17). We 
recruited only 600 women, again expecting misoprostol to be very much more 
effective than placebo. The result was a resounding disappointment. There was 
no significant reduction in blood loss with misoprostol. There were very high rates 
of shivering and pyrexia. 
3.7 Another new route of administration 
18. 8amigboye A, Merrell DA, Mitchel R, Hofmeyr GJ. Randomised comparison of 
misoprostol with syntometrine for management of third stage of labor. Acta Obstet 
Gynecol Scand 1998; 77: 178-182 
Low risk women in labor were randomly allocated to receive either misoprostol 
400 mcg rectally or Syntometrine 1 ampuole intramuscularly. Duration of third 
stage of labor, estimated blood loss postpartum and hemoglobin estimation post-
partum were all similar. Postpartum diastolic hypertension was more common in 
the Syntometrine group. No other apparent side effect was noted in either group. 
19. 8amigboye AA, Hofmeyr GJ, Merrell DA. Rectal misoprostol in the prevention 
of postpartum hemorrhage: a placebo-controlled trial. Am J Obstet Gynecol 1998; 
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179: 1043-1046. 
Women were randomly allocated to receive 400 mcg misoprostol or nonidentical 
placebo rectally after birth. Any excessive bleeding was actively managed with 
conventional oxytocic agents. Blood loss was measured directly. Blood loss of 
1000 mL or more occurred in 4.8% (13/270) of the misoprostol group and 7% 
(19/272) of the placebo group (not significant). Additional oxytocic therapy was 
required by 3.3% and 4.7%, respectively. No predominance of side effects, 
particularly shivering, was noted in the misoprostol group. The early active 
management of excessive bleeding with conventional oxytocic agents may have 
reduced the potential of the study to detect differences between the groups. 
I wish to acknowledge Dr Derek Merrell, consultant obstetrician at Natalspruit 
Hospital, for pioneering the rectal route of administration of misoprostol. We 
designed a randomized trial comparing misoprostol with oxytocin-ergometrine, 
conducted mainly by Dr Anthony Bamigboye, a registrar at Natalspruit hospital, 
which was to my knowledge the first report of misoprostol administered rectally 
(18). Blood loss was similar between groups, and shivering was not seen as a 
major side-effect. The rectal route has since become extremely popular for 
treatment of postpartum haemorrhage, though without robust evidence of its 
effectiveness. 
With the same team we conducted a second study at Natalspruit hospital 
comparing rectally administered misoprostol with placebo (19). The reduction in 
blood loss with misoprostol was not statistically significant. 
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3.8 Side-effects 
20. Hofmeyr GJ, Nikodem C, de Jager M, Drakely A, Gilbart B. Oral misoprostol 
for labour third stage management: randomised assessment of side effects (part 
2). Proceedings of the 17th Conference on Priorities in Perinatal Care; South 
Africa. 1998: 53-4. 
Women in labour were randomly allocated to receive misoprostol 400mcg or 
600mcg or placebo orally after the birth of the baby. Conventionaloxytocics 
were given immediately if blood loss was thought to be more than usual. The 
rate of shivering in the 3 groups was 81/199; 65/199; 30/199; pyrexia: 53/200; 
28/200,5/200. Blood loss >1000ml: 17/200, 16/200,6/200. 
21. Lumbiganon P, Hofmeyr J, Gulmezoglu AM, Pinol A, Villar J. Misoprostol dose-
related shivering and pyrexia in the third stage of labour. Br J Obstet Gynaecol 
1999; 106: 304-308 
In a randomized pilot study comparing misoprostol 600mcg vs 400 mcg vs 
oxytocin, the rates of shivering were 56/199 vs 38/198 vs 25/200, and pyrexia 
>38 degC 15/199 vs 4/195 vs 6/199. 
We conducted another study of oral misoprostol to see whether the side-effects 
were dose-related, comparing 600 micrograms versus 400 micrograms versus 
placebo, and confirmed that indeed the side-effects with 400 micrograms were 
fewer (20). Together with international colleagues, we subsequently confirmed 
this finding as part of our large World Health Organization trial (21). The data on 
blood loss in our trial (20) were even more disappointing. The rates of postpartum 
haemorrhage were 17/200 (8.5%) for 600 micrograms, 16/200 (8%) for 400 
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micrograms, and for placebo 6/200 % (3%)! As we did the analysis, we couldn't 
believe what we were seeing. We went over the data time and time again, 
convinced that we had made some error, but nothing changed. The lesson, of 
course, is a very important one in clinical research. In studies with relatively small 
numbers of outcomes, even if perfectly randomized, there is considerable scope 
for variation in the results due to chance. If the same small trial is repeated over 
and over, the results will tend to cluster around the 'true' result, but every now and 
then there will be a chance aberration which falls far away from the 'true' result in 
one or other direction. This trial is an example of an extreme outlier. One other 
trial of similar size conducted in France also showed a trend to more haemorrhage 
with misoprostol than with placebo (Benchimol et ai, 2001). This chance variation 
in the results of small trials is the cause of a fundamental limitation of meta-
analysis: publication bias. 
3.9 Chance variation and publication bias 
The randomized trial is the most reliable way of getting information close to the 
'true' effectiveness of an intervention, but there will always be some variation in 
the result, due to the play of chance. The smaller the number of cases with the 
outcome, the greater the degree of variation. If all the randomized trials 
conducted on the same intervention are synthesised by meta-analysis, the 
variations in each direction will cancel each other out and give a summary result 
close to the 'true' effect. 
To illustrate this principle in the research methods courses we run, I ask the class 
to each flip 2 coins at the same time, 10 times, and write down the number of 
times they get 2 heads. The results are all over the place, usually from 0/10 to 
about 7/10. We then enter all the results into a meta-analysis program, and as the 
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numbers build up, the summary effect always moves closer and closer, and ends 
up uncannily close to the 'true' result: 25%. 
The Achilles heel of meta-analysis in is that we don't have access to all the trials 
of an intervention which have been conducted. If we had access to a random 
sample of the trials that would also be fine, but in effect we have access to a 
biased sample of trials. What happens in real life is that not all the small trials of 
an intervention which are conducted, are published. All the trials represent the 
chance variation in the results ranging from more positive than the 'true' result to 
less positive. Those with more positive results are more likely to be published. 
Investigators getting less positive results tend to be discouraged, feel the results 
are not worth publishing, or their submissions are less likely to be accepted 
because they are not newsworthy. The literature available on which we base our 
policies and our practice is thus inherently skewed by this 'publication bias'. How 
should we deal with it? 
Firstly, we fortunately know that publication bias is invariably in the direction of 
over-estimating the effectiveness of an intervention. If meta-analysis of a new 
intervention shows no beneficial effect, we can safely conclude that the 
intervention is not effective. 
If meta-analysis of a number of small trials shows a beneficial effect, we need to 
keep in mind the possibility of publication bias, and the best solution is to use the 
meta-analysis as an hypothesis-generating exercise, and proceed to conduct a 
large, high-profile, international, multicentre 'mega-trial'. The mega-trial will 
invariably give a lower estimate of the effect of the intervention than the meta-
analysis of small trials, and will be a more reliable estimate of the true effect 
(Scifres et ai, 2009). There are many examples of this principle, such as our WHO 
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multicentre trial of calcium supplementation to reduce pre-eclampsia (Villar et ai, 
2006) which found a far smaller effect than our preceding meta-analysis (Hofmeyr 
Atallah & Duley, 1998), and our WHO misoprostol trial to which I shall refer below. 
I have given some time to the issue of publication bias as it is not a generally well-
acknowledged phenomenon, and is crucial to an understanding of the controversy 
surrounding misoprostol and postpartum haemorrhage which will emerge below. 
3.10 The WHO misoprostol for preventing postpartum haemorrhage 
trial 
22. GGlmezoglu AM, Villar J, Ngoc NN, Piaggio G, Carroli G, Adetoro L, Abdel-
Aleem H, Cheng L, Hofmeyr GJ, Lumbiganon P, Unger C, Prendiville W, Pinol A, 
Elbourne D, EI-Refaey H, Schulz KF, for the WHO Collaborative Group To 
Evaluate Misoprostol in the Management of the Third Stage of Labour. The WHO 
multicentre double-blind randomized controlled trial to evaluate the use of 
misoprostol in the management of the third stage of labour. Lancet 2001; 358: 689 
695. 
Measured blood loss of 1000 mL or more occurred in 366/927 women with 
misopropstol versus 263/9232 women with injectables (RR 1.39, 95%CI1.19 to 
1.63). Misoprostol use was associated with 3.5 times more shivering and 7 times 
more raised body temperature. 
23. Hofmeyr GJ, GGlmezoglu AM, Villar J, Lumbiganon P, Piaggio G. Effects of 
misoprostol on profuse blood loss after birth: an exploratory study of data from 
the WHO Randomised Trial of Misoprostol in the Third Stage of Labour 
(unpublished). 
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In the face of extremely erratic results of several smaller randomized trials, including 
those from our unit to which I have referred above, our network of researchers from 
low-income countries led by Metin Gulmezoglu from the World Health Organization 
decided to mount a mega-trial to determine the effectiveness or otherwise of 
misoprostol (22). We chose 600 mcg orally as the largest reasonable dose to use 
for 'proof of concept' (to minimize the risk of failing to detect an effect by choosing a 
sub-optimal dose). So high were our expectations that misoprostol would prove to 
be the solution to postpartum haemorrhage we were all searching for, that we set 
this up as an equivalence trial. We expected to prove, through enrolment of very 
large numbers of women, that misoprostol was more or less as effective as oxytocin. 
The results from recruitment of more than 18 000 women were another resounding 
disappointment. Misoprostol was considerably less effective than injectables. This 
left us with a monumental gap in our knowledge. We knew that misoprostol was 
less effective than injectables, but not having had a placebo group, we did not 
know how effective it was in absolute terms, or whether it was effective at all. To 
this day our evidence on the absolute effectiveness of misoprostol is based on 
data from a number of placebo controlled trials very much smaller than the WHO 
trial, with a wide range of results, and subject to the possibility of publication bias. 
Ironically, although this was essentially a negative result, because of the enormous 
scale of the trial, which numerically overwhelmed all other randomized trials in the 
area, 600 mcg became entrenched in the collective psyche as the 'WHO trial 
dosage'. 
My contention is that this fundamental disappointment in the less than expected level 
of effectiveness of misoprostol even at this high dosage, instinctively discourages 
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researchers and advocates from entertaining the use of a smaller dose. The 
600mcg used in the WHO trial became the benchmark for subsequent trials which 
have influenced global practice. 
An interesting anomaly in the WHO trial data was that despite a 40% higher 
number of women who lost 1 OOOml or more of blood, there was a trend to fewer 
blood transfusions in the misoprostol group than the oxytocin group. To determine 
whether this might be due to a reduction in massive blood loss, I developed a 
protocol and we conducted a post hoc analysis of higher levels of blood loss (23). 
We confirmed that for volumes of blood loss above 1750ml there was a trend to 
slightly fewer cases with misoprostol than with oxytocin. 
This was odd. Perhaps it was due to greater use of 'rescue' oxytocin in women in 
the misoprostol group who continued to bleed, or perhaps there was something 
about the action of misoprostol over time we did not yet understand. 
A very recent trial from India comparing powdered misoprostol 400mcg 
sublingually with oxytocin, found exactly the opposite effect as the large WHO trial: 
a 66% reduction in blood loss >500ml (8ellad et ai, 2012). This discrepancy is 
very difficult to understand. Either it was yet another chance finding, or the 
oxytocin was less effective than that used in the WHO trial, or for some reason we 
don't yet fully understand, 400mcg sublingually is more effective than the 600mcg 
orally used in the WHO trial. 
3.11 Different effects in different settings? 
Most trials of misoprostol for preventing postpartum haemorrhage have been 
conducted in hospital settings. In 2005 and 2006 three trials were reported from a 
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primary care setting in Guinea-Bissua (Hoj et ai, 2005) or community settings in 
India (Derman et ai, 2006) and Gambia (Walraven et ai, 2005), comparing 
misoprostol 600mcg sublingually or orally with placebo or (in Gambia) with oral 
ergometrine, which is considered to have negligible effect. In contrast to the 
inconsistent results of studies in hospital settings, these trails showed a consistent 
reduction in severe postpartum haemorrhage which was statistically significant for 
the Guinea-Bissau and the India trials. The findings in a subsequent community-
based trial in Pakistan (Mobeen et ai, 2011) were similar. The question arises 
whether misoprostol may be uniquely effective in community settings? It is 
plausible that in hospital settings, the availability of 'rescue' treatment with 
oxytocin may mask the benefits of misoprostol compared with placebo. Data from 
these trials were the basis for the WHO to recommend the use of misoprostol in 
community settings where oxytocin was not available. The dose recommended 
was 600mcg, as there were no community based trials of lower dosages to guide 
recommendations. 
3.12 The effect of misoprostol over and above oxytocin 
24. Hofmeyr GJ, Fawole B, Mugerwa K, Godi NP, Blignaut Q, Mangesi L, 
Singata M, Brady L, Blum J. Administration of 400 I-Ig of misoprostol to augment 
routine active management of the third stage of labor. Int J Gynaecol Obstet. 
2011; 112: 98-102. 
Blood loss of 500 mL or more was not significantly reduced by sublingual 
misoprostol 400 Jig versus placebo, in addition to standard oxytocin. (misoprostol 
22/546 [4.0%J versus placebo 35/553 [6.3%J; relative risk, 0.64; 95% confidence 
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interval, 0.38-1.07). Shivering and pyrexia occurred more frequently in the 
misoprostol group. 
25. Fawole AO, Sotiloye OS, Hunyinbo KI, Umezulike AC, Okunlola MA, 
Adekanle DA, Osamor J, Adeyanju 0, Olowookere 00, Adekunle AO, Singata M, 
Mangesi L, Hofmeyr GJ. A double-blind, randomized, placebo-controlled trial of 
misoprostol and routine uterotonics for the prevention of postpartum hemorrhage. 
Int J Gynaecol Obstet. 2011 ;112: 107-11. 
Blood loss of 500 mL or more was not significantly reduced by sublingual 
misoprostol400 Jig versus placebo, in addition to standard oxytocin (40/658 
[6.1%] vs 42/660 [6.4%], relative risk [RR] 0.96; 95% confidence interval [CIj, 
0.63-1.45); nor was blood loss of at least 1000 mL (4/658 [0.61%] vs 8/660 
[1.2%], RR 0.50; 95% CI, 0.15-1.66). Misoprostol was associated with pyrexia 
and moderate/severe shivering. 
Having shown conclusively that oral misoprostol 600mcg was much less effective 
than oxytocin (if effective at all), the next important question was: what about both 
together? 
For the past 12 years we have run an annual research methods course, funded by 
WHO and the Eastern Cape Department of health. About 30 prospective 
researchers from all over the continent come to East London for hands on training 
in randomized trial and systematic review methodology. We encourage them to 
develop a project and offer mentoring. One year, participants from Eastern Cape, 
Mpumalanga, Uganda and Nigeria agreed to tackle a trial of oxytocin plus 
misoprostol versus oxytocin plus placebo (24,25). Part of the exercise was to 
show that with committed staff and capacity-building for decentralized data 
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collection, high quality trials could be conducted without huge expenditure. Neither 
trial alone showed significantly reduced blood loss. However, when combined by 
meta-analysis with one previous study from Turkey using 400 mcg (orally), they 
added to the body of data showing an overall significant reduction of postpartum 
haemorrhage of about 30% when misoprostol 400mcg was added to the oxytocin 
regimen. 
3.13 Observational studies and clinical experience 
26. Hofmeyr GJ, Ferreira S, Nikodem VC, Mangesi L, Singata M, Jafta Z, 
Maholwana B, Mlokoti Z, Walraven G, Gulmezoglu AM, Misoprostol for treating 
postpartum haemorrhage: a randomized controlled trial [ISRCTN72263357]. 
BMC Pregnancy and Childbirth 2004; 4: 16. 
Women with postpartum haemorrhage received routine treatment with injectable 
utero tonics, and in addition misoprostol (200mcg orally, 400mcg sublingually and 
400mcg rectally) versus placebo. With misoprostol there was a trend to reduced 
blood loss ~500 ml (6/117 vs 11/120, relative risk 0.56; 95% confidence interval 
0.21 to 1.46). Side-effects were increased, namely shivering (63/116 vs 30/118; 
2.14, 1.50 to 3.04) and pyrexia> 38.5°C (11/114 vs 2/118; 5.69, 1.29 to 25). In 
the misoprostol group 3 women underwent hysterectomy of whom 1 died, and 
there were 2 further maternal deaths. 
27. Walraven G, Oampha Y, Bittaye B, Sowe M, Hofmeyr J. Misoprostol in the 
treatment of postpartum haemorrhage in addition to routine management: a 
placebo randomised controlled trial. BJOG. 2004; 111: 1014-7. 
Women with postpartum haemorrhage received routine treatment with injectable 
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uterotonics, and in addition misoprostol (200mcg orally and 400mcg sub/ingually) 
versus placebo. With misoprostol there was a trend to reduced blood loss ~500 
ml: 13179 (16.5%) 23/81 (28.4%) RR 0.58 95% CI 0.32 to 1.06 
28. Widmer M, Blum J, Hofmeyr GJ, Carroli G, Abdel-Aleem H, Lumbiganon P, 
Nguyen TN, Wojdyla 0, Thinkhamrop J, Singata M, Mignini LE, Abdel-Aleem MA, 
Tran ST, Winikoff B. Misoprostol as an adjunct to standard uterotonics for 
treatment of post-partum haemorrhage: a multicentre, double-blind randomised 
trial. Lancet. 2010; 375: 1808-13. 
Women with postpartum haemorrhage received routine treatment with injectable 
utero tonics, and in addition misoprostol 600 pg sublingually versus placebo. 
Blood loss of 500 mL or more after enrolment was similar between the 
misoprostol group (1001705 [14%J) and the placebo group (1001717 [14%]; 
relative risk 1.02, 95% CI 0.79 to 1.32). In the first 60 min, an increased 
proportion of women on misoprostol versus placebo, had shivering (4551704 
[65%] vs 2301717 [32%]; 2.01, 1.79 to 2.27) and body temperature of 38°C or 
higher (3031704 [43%J vs 1071717 [15%J; 2.88,2.37 to 2.50). 
Around this time, in contrast to the disappointing results of our early randomized 
trials on postpartum haemorrhage prevention, a number of observational studies 
were published which showed remarkable benefits from misoprostol used to treat 
postpartum haemorrhage in a variety of doses and by various routes of 
administration. In about 95% of cases reported, misoprostol given to women with 
postpartum haemorrhage was followed by almost immediate cessation of 
bleeding. The fact that in many cases the bleeding stopped before the 
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misoprostol could have been absorbed into the system did not deter clinicians 
from ascribing these dramatic effects to the misoprostol. 
The phenomenon of cessation of bleeding following misoprostol administration 
was experienced by doctors and midwives globally, and the clinical conviction 
entered the collective psyche of health professionals that misoprostol was a 
spectacularly effective treatment for postpartum haemorrhage. 
We set out to conduct the first ever placebo-controlled randomized trials of 
misoprostol for the treatment of postpartum haemorrhage. Gijs Walraven from the 
Reproductive Health Program of the MRC Research Laboratories in The Gambia 
visited us in East London, and together we planned similar protocols for trials to be 
run in South Africa (237 women) (26) and Gambia (160 women) (27). Most of the 
observational reports had used doses up 1000 mcg by various routes, mainly the 
rectal route. We decided to use a large dose including the rectal route to be sure 
not miss a beneficial effect through under dosing. We also hoped that using 
various routes, with differing rates of absorption, would reduce side-effects. In 
East London we chose to use 200 mcg orally plus 400 mcg sublingually plus 400 
mcg rectally. Gijs Walraven chose to use, based on what was acceptable and 
feasible in the Gambian context, 200 mcg orally plus 400 mcg sublingually. We 
compared the effect of misoprostol with placebo, over and above the effect of 
routine treatment which all women received. The trials showed remarkably similar 
results - a reduction in additional blood loss after enrolment which was not 
statistically significant, but became significant when the data from the two trials 
were combined by meta-analysis. A recent similar small trial conducted in 
Pakistan using misoprostol 600 mcg sublingually produced similar results (Zuberi, 
2008). 
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As before with prevention of postpartum haemorrhage, there was the need to 
confirm the results of small trials with a mega-trial, and once again we worked with 
our network of colleagues, co-ordinated by Metin Gulmezoglu at the World Health 
Organization, to repeat our studies, this time using 600 mcg sublingually. Yet 
another profound disappointment. After using conventional treatment, misoprostol 
had absolutely no additional measurable effect compared with placebo (28). 
What was the truth? The effects ranging from modest to zero shown by our three 
randomized trials, or the dramatic effects experienced in clinical practice in the 
treatment of postpartum haemorrhage? 
The crux of this common dissonance between clinical experience and randomized 
clinical trials lies in the question: "What would have happened in clinical practice 
had placebo been given instead of misoprostol?" 
Medical practice is a very satisfying field in which to work, much more so than, 
say, repairing motor cars. Generally, people consult a doctor when they are 
unwell. Most illnesses are self-limiting. It is inevitable that health professionals 
are exposed to an unrealistically favourable impression of the effectiveness of 
what they do. Cars seldom recover without somebody doing something effective. 
One may say, "So what?" The patient is better, the doctor feels good, what does it 
matter whether the recovery was assisted by the medication or not? 
3.14 "At least it does no harm" 
Once upon a time, doctors developed a new treatment for women at risk of 
miscarriage (mainly women who had previously suffered miscarriage). In contrast 
to their previous history of miscarriage, more than 9 out of 10 women who 
received the new treatment had a successful pregnancy. These results were 
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wonderful, and the treatment became widely practiced as standard care. Unlike 
many other impressively effective interventions which are part of our everyday 
practice, this treatment was tested in a randomized trial. The trial confirmed that 
more than 9 of 10 women who received the treatment had a successful 
pregnancy. What was unexpected, was that women who were randomly allocated 
to receive an identical-looking placebo (blank) tablet had identically good 
outcomes. The treatment itself had absolutely no beneficial effect. 
The results of this trial were presented at a meeting of the American College of 
Obstetricians and Gynecologists. In the published discussion following the 
presentation, proponents of the treatment stated that their personal results with 
the treatment were so good that they were unconvinced by the trial findings, and 
would continue to use the treatment. Over the next 2 decades, over 2 million 
women received this treatment, which was known to be ineffective. Such is the 
power of the personal conviction of clinicians. The good thing was that there 
appeared to be no adverse effects. The doctors were happy, and the women 
were happy with the excellent pregnancy outcomes. Why be bothered? 
Time passed and a strange thing happened. A few young women in the Boston 
area developed cancer of the vagina. Had they developed breast cancer, the 
event would have passed unnoticed. But vaginal cancer was exceptionally rare, 
and doctors started searching for an explanation. It came to light that the mothers 
of these women had received the treatment to prevent miscarriage. Panic 
ensued. The offspring of women enrolled in the original trial were tracked down 
and asked to undergo health checks. Fortunately the incidence of vaginal cancer 
was very low, but compared with the offspring of women who had received the 
placebo tablets, these young men and women had an excess of multiple health 
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problems, including vaginal adenosis, abnormally shaped uteri, recurrent 
miscarriages, testicular hypotrophy, infertility and psychiatric illness. 
None of these adverse effects would have come to light had it not been for the 
sheer fluke that one of the side-effects (vaginal cancer) was so extremely unusual 
that it elicited the interest of the astute pathologists who dealt with some of the 
cases. Theirs is the credit that, unlike many other medicines of unproven 
effectiveness, the hormone diethylstilboestrol (DES) is no longer given to pregnant 
women on the basis of "well, it doesn't do any harm" (that we know of). 
3.15 Back to misoprostol 
What does this have to do with misoprostol? The enthusiasm with which 
misoprostol was embraced by clinicians as a treatment for postpartum 
haemorrhage, based on striking personal experience, was out of all proportion to 
the evidence overall from randomized trials that misoprostol has little if any benefit 
over and above oxytocin. The most recent report on Confidential Enquiries into 
Maternal Deaths in South Africa, to which I have referred previously with respect 
to ruptured uteri following labour induction with misoprostol, highlighted the fact 
that in the face of life-threatening postpartum haemorrhage following treatment 
with oxytocin, clinicians all too often chose to use rectal misoprostol rather than 
the recommended second line treatment, ergometrine (2). 
We need to analyse the clinical context in which misoprostol is used for treatment 
of postpartum haemorrhage. This is a particularly terrifying condition with which to 
be faced. I know only too well the sense of impending doom when the bleeding is 
profuse and relentless and seems incompatible with survival of the mother. Our 
instinct is to use any method which may possibly help to arrest the bleeding. It is 
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quite understandable that even doctors who are aware of the evidence that once 
injectable uterotonics have been given, misoprostol has no proven additional 
benefit, and may cause harm, in this situation argue "she is dying, we have to do 
something". 
Similarly, at a public health policy level, faced with the ongoing global maternal 
mortality from haemorrhage, the compelling argument is "Women are dying every 
day, we have to do something now" (Potts & Hemmerling, 2006). 
Instinctively, when faced with possible disaster, we want to do something. 
3.16 The global debate 
Early on, the issue of misoprostol after childbirth became an issue of considerable, 
and unfortunately heated, global debate. Misoprostol represented a ray of hope 
for a way of overcoming our appalling lack of progress in reducing maternal 
mortality in poor countries, despite the rhetoric of the Millenium Development 
Goals. There was intense pressure from global agencies and advocates to 
implement large-scale programs using misoprostol routinely after childbirth to 
prevent postpartum haemorrhage. 
On the surface, the arguments regarding rapidly upscaling misoprostol programs 
were as follows: 
Con: we need more trials to be sure that misoprostol does more good than harm. 
Pro: we can't wait for more trials while women are dying. 
In several years' time we would probably have more certainty as to whether 
misoprostol does more good than harm. If we implemented programs and it 
turned out to be harmful, we would be responsible for causing harm through an 
inadequately tested intervention. If we did not implement its use and it turned out 
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to be effective, we would be responsible for withholding a lifesaving intervention 
while women died. Damned if you do and damned if you don't. It was an 
impossible choice which decision-makers had to make, and be prepared to face 
the consequences. 
Rationally, if we don't yet know whether the intervention will do more good than 
harm, we know that doing nothing may in fact save lives. However, our human 
instinct is such that faced with impending death or deaths, doing something with 
the possibility of improving outcomes is at an emotional level a more attractive 
proposition than doing nothing, with the possibility of avoiding more harm. 
It is perhaps because of his knowledge of human nature that Hippocrates found it 
necessary to counteract this tendency with the specific injunction: "First, do no 
harm." 
3.17 New drugs versus drugs already on the market 
The fact that the dilemma arose at all was due to the fact that misoprostol was 
already widely available for other indications. Had it been a new drug being 
developed for use after childbirth, it would not have been allowed to be distributed 
before there was a large and systematic body of evidence of both safety and 
effectiveness. This process usually takes a drug company 10 to 20 years and 
multiple millions of dollars to complete. Misoprostol had the potential to skip this 
process, and there was enormous pressure for it to do so, with the attendant risks. 
For reasons which will become apparent, I was opposed to widespread use of 
misoprostol after childbirth in the dosage being recommended (600 mcg) without 
more evidence of safety. My personal evaluation of the total body of scientific 
evidence available was that at a dosage of 600 mcg or more there was a real 
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possibility of doing more harm than good, whereas at 400 mcg or less, the risk of 
harm was considerably less, and the balance of probability was in favour of benefit 
over harm. 
Time and again in international meetings and expert committees I argued for 
caution and use of a smaller dosage, against an overwhelming lobby of global 
organizations pushing for immediate implementation at the higher dose. Debates 
often became heated, but for the most part I failed to convince any of the 
advocates of implementation of my point of view. It is not an easy proposition to 
sell, because it is essentially counter-intuitive. One important aspect is a fatal flaw 
in the argument for misoprostol: the use of a proxy outcome. 
3.18 How proxy outcomes may be misleading 
In clinical research, when the health outcome of concern cannot be measured 
directly, we may make use of a 'proxy' outcome - a measurable outcome which 
serves as a substitute for the more critical outcome. 
The primary purpose of using misoprostol after childbirth is to reduce maternal 
deaths from haemorrhage. The argument appears compelling: 
1 . Haemorrhage is a major cause of maternal death 
2. Misoprostol reduces haemorrhage after childbirth 
3. Therefore use of misoprostol will reduce maternal deaths 
My argument, which was far less persuasive, was as follows: 
1. Misoprostol reduces blood loss modestly, but also has powerful effects on 
multiple organ systems including the cardiovascular system. 
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2. It is possible that adverse effects on other homeostatic mechanisms might 
cause more deaths than those prevented by reduced blood loss, particularly when 
used in large dosages (the data which suggested this possibility will emerge 
below). 
In 'misoprostol' circles, this was an exceptionally unpopular heresy. I remember 
after suggested this possibility during an international presentation (Hofmeyr, 
2006), one of my colleagues from a global agency approached me in great 
distress and said "You just can't say that!" It was so undermining of what 
everyone was working for that it could not even be contemplated. 
Yet there are examples of just such counter-intuitive dissonance between a proxy 
outcome and the primary outcome of concern. A good example is the use of 
certain antiarrhythmic agents following myocardial infarction. The proposition was: 
1. Arrhythmias (ventricular premature depolarizations) are a common cause of 
death following myocardial infarction 
2. Anti-arrhythmic agents reduce arrhythmias (proxy outcome) following 
myocardial infarction 
3. Therefore anti-arrhythmic agents should reduce deaths 
On this basis, anti-arrhythmic agents were widely used to reduce death following 
myocardial infarction. However, a randomized trial large enough to measure 
death rather than the proxy outcome of reduced arrhythmias was conducted by 
the CAST group (Epstein et ai, 1993). Men and women (3549 of them) who had 
suffered myocardial infarction with left ventricular dysfunction were randomly 
assigned to receive ant-arrhythmic agents or placebo. Death within 1 year was 
significantly more common in those who receive the anti-arrhythmic agents (10%) 
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than those who received placebo (5%). It has been estimated that tens of 
thousands of men and women were killed by the well-meaning use of anti-
arrhythmic agents, based on a logical extrapolation from a proxy outcome. 
The same might conceivably apply to the apparently logical use of misoprostol 
following childbirth, but a trial large enough to measure death as an outcome is 
unlikely to be feasible, so the truth will be more difficult to discern. 
Another example of an apparently logical intervention which did more harm than 
good was formula feeding for women with HIV infection living in low-resource 
settings. It seemed self-evident that avoiding the risk of HIV infection via breast 
milk would improve the babies' chances of survival. A small group of researchers 
in South Africa opposed this policy on the basis that the risks of formula feeding in 
this setting probably outweighed the benefits. In time, evidence emerged that in 
this setting more babies died from complications of formula feeding than 
contracted HIV from breastfeeding, but it took years and considerable loss of life 
before the policy was changed (Coutsoudis Coovadia & Wilfert, 2008). 
3.19 Postpartum haemorrhage as the Trojan horse 
There was another layer to the misoprostol for postpartum haemorrhage issue 
which I never heard mentioned in public, but which I now understand contributed 
to the vehemence with which my call for caution in implementing misoprostol for 
postpartum haemorrhage was met. The unspoken issue was abortion. The one 
context in which misoprostol is undeniably life-saving is as a method of safe 
abortion. Widespread distribution of misoprostol ostenSibly for use after childbirth, 
clearly makes misoprostol available in the community for use for safe abortion. As 
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abortion is illegal in many countries, postpartum haemorrhage was seen as a 
politically persuasive alternative for distribution of the medication. 
Although I never heard the abortion issue mentioned, it was the only explanation I 
could give for the seemingly excessive diligence with which the misoprostol for 
postpartum haemorrhage agenda was promoted. Only in 2011 was my 
assumption confirmed in a Family Care International report entitled "Mapping 
Misoprostol for Postpartum Hemorrhage: Organizational activities, Challenges and 
Opportunities". Over 30 organizations were surveyed. One of the summary pOints 
was: "Rather than hiding misoprostol's abortion indication to avoid controversy, 
this indication should be presented as one of many ways misoprostol can 
potentially save women's lives." Quotes from respondents included: "Because 
misoprostol for postpartum haemorrhage is less controversial than misoprostol for 
safe abortion, it is a "door-opener";" and another: "Go under the radar. Introduce 
misoprostol for noncontroversial uses, such as postpartum haemorrhage, with the 
tacit understanding that it may also be used for abortion." 
Ironically, advocates of misoprostol distribution assumed that my reason for 
caution regarding misoprostol distribution was that I must be anti-abortion (I was 
informed by a representative of a global agency that this was a widely held 
opinion). This is an understandable projection: those following an undisclosed 
agenda will assume that others are as well. 
3.20 Abortion 
Because the abortion agenda has distorted the misoprostol after childbirth debate 
so profoundly, it is important that I declare any potential conflict of interest and 
place on record my personal standpoint on abortion. 
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This has two aspects: equity, and personal experience. 
On the grounds of equity, my view is that any restriction placed on women's 
access to safe abortion is unenforceable against women with wealth and therefore 
fundamentally unjust. In South Africa when abortion was restricted (prior to 1995), 
wealthy women travelled to Swaziland or London for safe unspecified 
'gynaecological procedures', while those of us working in state hospitals dealt with 
the indescribable misery, mutilation and death following the 'backstreet' abortion 
attempts of those less affluent. We did all we could by way of treatment, blood 
transfusion, removing rotten uteri, ventilation in ICU, but all too frequently the 
young women died. 
Because I have the technical ability to provide safe abortions and I work in the 
public sector with women without access to private care, I regard it as my duty to 
do everything in my power to ensure that our clients have the same access to safe 
abortion as their wealthy counterparts. One might call this the Dr Larch principle 
(from 'Ciderhouse Rules'). It is not a question of right or wrong or moral or 
immoral; it is a question of equity between rich and poor. I have also done as 
much as I can to promote access to quality family planning services so that fewer 
women are faced with this painful dilemma. 
The second issue is personal. Over almost 40 years of clinical practice I have sat 
face to face and counselled countless women requesting abortion. I do not recall 
a single case in which my human instinct was not to support the woman in the 
painful choice she had made. The dilemma faced by women requesting abortion 
is well illustrated by a response from a participant in one of our research projects 
relating to abortion: "I love this baby, but I know that if I keep the baby I will lose 
my job and not be able to feed the child I already have". 
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If abortionists do end up in Hell, I will have thoroughly earned my place there. 
3.21 The Journal of the Royal Society of Medicine review 
There has recently been a further twist to the misoprostol for postpartum 
haemorrhage saga. A review in the JRSM argued that the evidence for the use of 
misoprostol in home and community settings in low- and middle income countries 
was weak and inconclusive, and called on the WHO to rethink their inclusion of 
misoprostol in the Essential Medicines List ( Chu Brhlikova & Pollock, 2012). I 
personally found the review scientifically unconvincing, but that is beside the point. 
What is interesting is the ideological undertones which emerged in the subsequent 
correspondence published in the Journal. 
Malcolm Potts and co-authors wrote: "Their paper is a sad example of workers in 
an elite setting advocating policies with the potential to endanger the lives of 
thousands of vulnerable women in low resource settings." 
Nancy L Kerr wrote: "I write due to concern that persons who wish to restrict 
misoprostol from the women of the world, because of personal biases, might 
attempt to use this article to influence policy." 
Richard Derman wrote: " .. there is no excuse for the lack of awareness of the 
methodologically stringent review and meta-analysis, (Sloan et ai, 2010) which 
clearly demonstrates that methodologically sound studies find a substantial and 
highly significant benefit in the provision of misoprostol for postpartum 
haemorrhage prevention." 
Two of the authors of the original paper responded to Derman's letter and 
concluded: "On the basis of current evidence the WHO should rescind its recent 
60 
decision to add misoprostol to the EML. An investigation into the organisations, 
networks and motives including potential conflicts of interests behind the 
promotion and research into misoprostol use is long overdue." 
3.22 Misoprostol dosage: abortion and postpartum haemorrhage 
Another unfortunate influence which may originate from the abortion agenda, 
relates to the dosage of misoprostol used for prevention and treatment of 
postpartum haemorrhage. As mentioned, I have for many years put forward, 
based on a systematic review of the literature, what I regard as a scientifically 
sound recommendation that the dosage of misoprostol used for prevention (and 
probably treatment) of postpartum haemorrhage should not exceed 400mcg. I will 
give full details of the research below. I have found it difficult to understand why 
my colleagues have been so reluctant to take my proposals seriously. It is only 
recently, in the light of understanding that the abortion and postpartum 
haemorrhage issues are intertwined, that it has occurred to me that researchers 
and advocates approaching the postpartum haemorrhage issue from an abortion 
perspective, would intuitively favour a dosage which was also appropriate for 
abortion (600 to 800 mcg). It is also understandable that those with long 
experience in the abortion field, where these doses have been well shown in a 
huge body of research to be effective and safe for abortion, should expect such 
doses also to be safe after childbirth. 
3.23 Misoprostol dosage after childbirth 
It will have become clear in the previous discussion of misoprostol for labour 
induction, that the dosage of misoprostol at different stages of pregnancy differs 
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enormously, and is an important issue. Prior to 20 weeks of pregnancy, a 
woman's uterus is relatively resistant to misoprostol, and fairly large doses are 
needed to stimulate uterine activity. Doses of misoprostol around 600 to 800 mcg 
are required for abortion, and are extremely safe. Towards the end of pregnancy, 
the uterus becomes exquisitely sensitive to misoprostol: doses as low as 25 mcg 
carry a measurable risk of causing hyperstimulation of the uterus and distress in 
the baby, and occasionally catastrophic rupture of the uterus. 
After childbirth, there is no biological reason to expect that the sensitivity of the 
uterine muscle to misoprostol would suddenly and dramatically decline. However, 
when I and my colleagues around the world started to research this field, we 
decided, in keeping with sound scientific principles, that for the purpose of 'proof 
of concept', we should start our research with the highest dose considered safe. If 
this was effective, we could reduce the dosage to find the lowest effective dose. 
As, after birth of the baby, the main known risks (fetal distress and ruptured 
uterus) were removed (barring in the event of an undiagnosed, unborn second 
twin), we considered around 600 mcg to be a safe upper limit dosage with which 
to begin. Our mistake was to assume that the risks were limited to fetal distress 
and uterine rupture. 
3.24 Misoprostol does more than contract the uterus 
In 1996 I met Y S Chong, a young registrar from Singapore, at the Third 
International Scientific Meeting of the Royal College of Obstetricians and 
Gynaecologists in New Delhi. He presented an elegant study in which he and 
colleagues had measured intrauterine pressure after childbirth in healthy women 
volunteers treated with oxytocin-ergometrine or oral misoprostol 200, 400, 500, 600 
or 800 mcg (Chong Chua & Arulkumaran, 1997; Chong et ai, 2001). The onset of 
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increased uterine activity was significantly slower with misoprostol than with 
oxytocin-ergometrine. There was no statistically significant difference in the 
measured pressures between the five misoprostol dosages. The ih woman to 
receive misoprostol 800 mcg developed life-threatening hyperpyrexia requiring life-
support in ICU. She pulled through, but it is difficult to imagine the anxiety of 
researchers facing the situation of a previously healthy volunteer fighting for her life 
following a purely physiological experiment of no benefit to her. This severity of side-
effect had never, to my knowledge, been described amongst hundreds of thousands 
of women receiving the same dose of misoprostol for abortion. This was the first 
intimation that after childbirth, women might be uniquely vulnerable to the multiple 
hormonal effects of misoprostol (other than effects on the uterus). In retrospect, this 
is biologically not surprising. 
The period immediately before and after childbirth is one of profound physiological 
instability, with release of high levels of endogenous hormones such as oxytocin, 
prostaglandins, prolactin and catecholamines, and profound cardiovascular 
readjustment following the birth. The possibility that a powerful prostaglandin 
analogue with ubiquitous effects on multiple organ systems, including 
thermoregulation, coagulation, the gastrointestinal system and vascular tone, might 
interact with these turbulent homoeostatic processes in a unique and dangerous 
way, is far from implausible. 
The mistake we made, and which is still being made today, was to view misoprostol 
in a one-dimensional way, in terms of its effects on the uterus, and with insufficient 
attention to its many other effects on human physiology. We viewed misoprostol 
simplistically as an alternative uterotonic to oxytocin, failing to recognize that 
whereas oxytoxin has very specific effects on a limited number of tissues such as the 
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uterine muscle and the breast myoepithelial cells, prostaglandin receptors are 
present throughout the human body. A simple example of this dichotomy was our 
finding referred to in the chapter on labour induction, that misoprostol stimulated both 
rat ileal and uterine smooth muscle, whereas the oxytocin effect was specific to 
uterine muscle (14). 
That misoprostol might have dangerous side-effects should not be unexpected. 
Sulprostone, a prostaglandin E2 analogue has been registered for the treatment of 
postpartum haemorrhage in France for many years. There have been several 
reports of serious side-effects including cardiac arrest (Cheng Koh & Chong, 1998) 
and hyperpyrexia with neurological symptoms (Cellier et ai, 2012). 
It is my contention that the potential risks of high dose misoprostol after childbirth 
continue to be underplayed in the context of the global imperative to improve 
outcomes for women by promoting widespread distribution of misoprostol. 
It is most unfortunate that the adversarial climate engendered by the abortion issue, 
has created a situation in which well-intentioned proponents of misoprostol need to 
play down the risks in order to minimize the ammunition available to the anti-
misoprostollobby. 
Chong and colleagues' finding of no difference in the effect of misoprostol on uterine 
contractions after childbirth in dosages from 200mcg upwards has been confirmed in 
a randomized study showing no difference in postpartum uterine contractions 
between sublingual misoprostol 200, 400 and 600 mcg (Elati et ai, 2011). The rate 
of hyperpyrexia >39 degrees C increased from 8.3% with the lower dosages to 45% 
with 600mcg. 
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3.25 What else causes reluctance to lower the recommended dosage of 
misoprostol following childbirth? 
I have suggested above that the link with abortion has primed researchers and 
advocates with a long experience of abortion to perceive 600 to 800 mcg as a 'safe 
and effective' dose, and one which allows convenient translation from the 
postpartum to the abortion indication. 
However, I wish to suggest that there is another human factor which evokes an 
instinctive reluctance to lower the dosage of misoprostol used after childbirth. This 
relates to the disappointing degree of effectiveness of misoprostol for preventing or 
treating postpartum haemorrhage. Because of an intuitive link between dosage and 
effect, we are reluctant to consider reducing the dosage of a compound which even 
in high dosage is less effective that we had hoped it would be. 
3.26 A new method of measuring postpartum intra-uterine pressure 
29. Pipingas A, Hofmeyr GJ, Sesel KR (1993). Umbilical vessel oxytocin 
administration for retained placenta: in vitro study of various infusion techniques. 
Am J Obstet Gynecol 168: 793 
Contrast medium was injected into the umbilical vessels of 25 freshly delivered 
placentas and sequential x-ray films were taken. Capillary filling was inconsistent 
after injection of 20 ml of solution into the umbilical vein without or with "milking" 
of the cord (1/5 and 215, respectively). These were the techniques most 
commonly used in reported controlled clinical studies. Injection via an infant 
mucus aspiration catheter introduced along the umbilical vein to 5 cm from the 
placental insertion demonstrated a cotyledonary pattern in three of five cases 
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after 20 ml and in all 5 after 30 mi. 
30. 8amigboye A A, Hofmeyr GJ, Nikodem VC. Measuring postpartum uterine 
contractions during the third stage of labour: a pilot study, using a novel minimally 
invasive technique. Open Journal of Obstetrics and Gynecology 2011; 1: 128-
130 
The study showed that postpartum intra-uterine pressure could be measured 
non-invasively with a pressure catheter inserted via the umbilical vein into the 
placenta. 
I mentioned above the work of Chong and colleagues on the physiological effects of 
various dosages of misoprostol on contractions of the uterus after birth (Chong et ai, 
2001). Contractions were measured with a pressure-tip catheter inserted into the 
uterus after birth of the baby. This is the 'gold standard' method of measuring 
postpartum intrauterine pressure, but exposes the mother to the risk of introducing 
infection from the birth canal to the uterus. I came up with an idea for a less invasive 
method, by introducing the pressure tip catheter through the umbilical vein into the 
placenta, and thus measuring pressure in the uterus while the placenta was still 
inside the uterus, without the catheter coming into contact with the mother's tissues. 
The idea probably originated from a problem I had had to solve some time 
previously: At the time, there was global interest in a non-invasive method of 
assisting the birth of a retained placenta (one which had not separated from the 
inside of the mother's uterus), by injecting oxytocin into the umbilical vein 
(misoprostol was also tried). The idea was that the oxytocin would diffuse from the 
placenta to the uterine muscle causing contraction of the muscle and thus shearing 
off the placenta. However, there was no evidence as to whether the injected 
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oxytocin reached the placenta. I had the idea of delivering the oxytocin more directly 
to the placenta by injecting it through a long catheter introduced along the umbilical 
vein to the placenta itself, rather than injecting peripherally into the vein as had been 
done up to this time. To test the effectiveness of this method, I developed an in vitro 
model whereby radio-opaque dye was injected via the catheter into a freshly-
delivered placenta under Xray screening. I supervised one of our registrars at 
Baragwanath Hospital, Dr A Pipingas, to carry out a series of tests, and showed that 
provided at least 30ml of dye was injected via the catheter, the dye perfused to the 
periphery of the placental cotyledons (29). I mentioned the work to lain Chalmers 
who was guest speaker at the 8th Priorities in Perinatal Care conference at 
Mpekweni in 1989. His National Perinatal Epidemiology Unit in Oxford was 
embarking on a large trial in collaboration with Memo Carroli of the Centro Rosario 
de Estudios Perinatales in Argentina, and they were able to at the last minute, 
incorporate the technique into their trial (Carroli et ai, 1998). The method was also 
used in a subsequent large multicentre trial (Weeks et ai, 2010). Injecting oxytocin 
into the placenta has not proved to be a useful method for removing a retained 
placenta, but the idea of accessing the placenta with a long catheter via the 
umbilical vein remained. 
When searching for a non-invasive method of measuring postpartum intra-uterine 
pressure, this previous innovation probably acted as a catalyst for the idea of again 
using the umbilical vein for access to the placenta within the uterus. I supervised 
one of our registrars at Coronation Hospital, Dr Anthony Bamigboye, to conduc~ a 
series of experiments which showed it to be a feasible method (30). 
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3.27 Reviews of misoprostol for preventing or treating postpartum 
haemorrhage 
31. Hofmeyr GJ, Gulmezoglu AM. Misoprostol in the third stage of labour and 
maternal mortality: a review. BMJ 2006. Rapid response to: Hf2Jj L, Cardoso P, 
Nielsen BB, Hvidman L, Nielsen J, Peter Aaby P. Effect of sublingual misoprostol 
on severe postpartum haemorrhagein a primary health centre in Guinea-Bissau: 
randomised double blind clinical trial BMJ 2005; 331: 723 
32. Hofmeyr GJ, Walraven G, Gulmezoglu AM, Maholwana B, Alfirevic Z, Villar 
J. Misoprostol to treat postpartum haemorrhage: a systematic review. 
BJOG. 2005; 112: 547-53. 
33. Gulmezoglu A, Forna F, Villar J, Hofmeyr G. Prostaglandins for preventing 
postpartum haemorrhage. Cochrane Database Syst Rev. 2007. 18; CD000494 
34. Hofmeyr GJ. Medical treatment of postpartum haemorrhage. O&G Forum 
2010,20 
One of the dilemmas facing researchers, clinicians, policymakers and advocates for 
women's health, is the fact that the results of scores of randomized trials using 
variable dosages and routes of administration in thousands of women under variable 
circumstances are exceptionally variable and contradictory. It is clear from the 
debate surrounding the Journal of the Royal Society of Medicine review discussed 
above, that different reviewers interpret the same information quite differently. We 
have, over the years published several reviews, all founded in the well-established 
methodology used for Cochrane systematic reviews (31-34). For the purposes if this 
dissertation, I will focus only on the extensive WHO Bulletin review referred to below. 
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3.28 Are there any other options? 
35. Hofmeyr GJ, Abdel-Aleem H. Prevention of postpartum hemorrhage in the 
absence of uterotonics. Int J Gynaecol Obstet. 2006; 94 Suppl 2:S 124-5 
We highlight the potential role of uterine massage for preventing postpartum 
haemorrhage, particularly in setting with no access to pharmaceutical 
u tero tonics, and call for relevant research. 
36. Abdel-Aleem H, Hofmeyr GJ, Shokry M, EI-Sonoosy E. Uterine massage 
and postpartum blood loss. Int J Gynaecol Obstet. 2006; 93: 238-239 
All women received oxytocin. Blood loss >500ml with uterine massage occurred 
in 4/98 versus 8/102 without (RR 0.52, 95% CI 0.16 to 1.67). Additional 
uterotonics were used in 5/98 versus 26.102 respectively (RR 
0.20, 95% CI 0.08 to 0.50). 
37. Abdel-Aleem H, Singata M, Abdel-Aleem M, Mshweshwe N, Williams X, 
Hofmeyr GJ. Uterine massage to reduce postpartum hemorrhage after vaginal 
delivery. Int J Gynaecol Obstet. 2010; 111: 32-6 
Three groups were compared. Uterine massage alone was less effective than 
oxytocin alone. The comparison of uterine massage plus oxytocin versus 
oxytocin alone was inconsistent between sites. 
38. Hofmeyr GJ, Abdel-Aleem H, Abdel-Aleem MA. Uterine massage for 
preventing postpartum haemorrhage. Cochrane Database Syst Rev. 2008. 16; 
CD006431. 
The review found insufficient evidence and called for more research. 
39. Novikova N, Hofmeyr GJ. Tranexamic acid for preventing postpartum 
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haemorrhage. Cochrane Database Syst Rev. 2010: CD007872. 
Blood loss greater than 400 ml was less common in women who received 
tranexamic acid after vaginal birth or caesarean section in the dosage of 1 g or 
0.5 g intravenously (risk ratio (RR) 0.51; 95% confidence interval (CI) 0.36 to 
0.72; two studies, 453 women). 
A standard element of management of postpartum haemorrhage is to "rub up" the 
uterus. This is based on the clinical observation that the uterus responds to manual 
stimulation by palpably contracting, and this appears to reduce blood loss. The 
presumed mechanism is that mechanical stimulation releases endogenous 
uterotonic hormones, mainly prostaglandins, causing contraction of the uterus. This 
is analogous to stimulation of the lower uterine segment manually or with a Foley 
catheter bulb which has been proved to promote labour induction (as discussed in 
the section on labour induction). 
Why not use uterine massage prophylactically to prevent postpartum haemorrhage? 
Uterine massage has long been used as part of the package 'Active management of 
the third stage of labour', but remarkably little attention has been given to testing 
whether it is effective or not. If uterine massage were indeed effective, it would be 
the ideal method, as it could be practiced anywhere, without dependence on supply 
of medications, and would be free of pharmacological side-effects (35). We 
collaborated with our colleagues in Assuit University to conduct 3 small randomized 
trials, the first in Egypt (36), and two simultaneously in Egypt and South Africa (37). 
The results were inconsistent, and may have been distorted by the concomitant use 
of oxytocin, and the fact that uterine massage might artificially increase measured 
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blood loss by expelling blood which would otherwise have pooled in the uterus. In a 
Cochrane systematic review of the subject, we emphasized the need for more 
research, particularly in settings with no access to uterotonic agents, where any 
benefits of uterine massage would be easier to demonstrate (38). 
It is striking that in comparison to the hundreds of research papers on misoprostol, 
there have been no other trials on the effectiveness or otherwise of uterine massage. 
This highlights again the bias of medical research towards drug-based research, and 
is analogous to the relative lack of research on the Foley catheter for labour 
induction discussed previously. 
An indication of the unusual enthusiasm for misoprostol is given by the fact that our 
review of tranexamic acid, another promising medication for treating postpartum 
haemorrhage, included only two studies (39). 
3.29 Outvoted in Bellagio 
In 2006 Helena von Hertzen from WHO arranged an ad hoc working group who met 
in Bellagio to develop guidance for the use of misoprostol. The guidance produced 
was published in a series of papers in the international Journal of Gynaecology and 
Obstetrics. I was the lead author on the paper on Misoprostol for treatment of 
postpartum haemorrhage and a co-author on the paper on misoprostol for 
prevention of postpartum haemorrhage. I tried very hard to convince my colleagues 
that a lower dose would be a safer option, but unsuccessfully, and the consensus 
was to recommend 600 mcg for both purposes. Rather that have my name 
associated with a recommendation I considered not the safest option, I withdrew 
from authorship of both papers (Alfirevic et ai, 2007, Blum et ai, 2007). 
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3.30 Balancing benefits and risks, and the dosage of misoprostol after 
childbirth 
The line of thought which I have tried (unsuccessfully for the most part), through 
multiple publications, presentations and expert meetings, to persuade my colleagues 
to follow, is as follows: 
1. The plausible benefits of misoprostol after childbirth are limited to improved 
contraction of the uterus which might reduce blood loss and thus the risk of death. 
2. Physiological and clinical studies have shown no significantly greater effect of 
doses of 600 mcg or more over that of 400mcg. 
3. The known and measurable side-effects (mainly pyrexia and shivering) are 
clearly dose-related. 
4. More importantly, as with any potent medication, there is the possibility of 
other, unknown adverse effects which are also likely to be dose-related. In general, 
beneficial effects of drugs plateau at a certain dosage. When it comes to poisoning, 
there is no upper limit to the increase in harm. 
5. In the context of routine, prophylactic use of a medication in all childbearing 
women, most of whom would not have developed postpartum haemorrhage and 
therefore would not benefit from the medication, the greatest emphasis should be on 
safety. 
6. For these reasons, programs to distribute misoprostol widely for use by 
women following childbirth should use a higher dose only if there is robust evidence 
that such a dose is more effective than a lower dose. 
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7. Currently, there is no evidence that 600 mcg is more effective than 400 mcg. 
3.31 Misoprostol after childbirth and the risk of death 
40. Hofmeyr GJ, Gulmezoglu AM, Novikova N, Linder V, Ferreira S, Piaggio G. 
Misoprostol to prevent and treat postpartum haemorrhage: a systematic review 
and meta-analysis of maternal deaths and dose-related effects. Bull World 
Health Organisation 2009; 87: 666-77 
We analyzed 46 trials with more than 40 000 participants. Of 11 deaths reported 
in 5 trials, 8 occurred in women receiving 600 Jig or more of misoprostol (Peto 
odds ratio, OR: 2.49; 95% CI: 0.76 to 8. 13). Meta-analysis of direct and adjusted 
indirect comparisons of the results of randomized trials showed no evidence that 
600 Jig are more effective than 400 Jig for preventing blood loss ~ 1 000 ml (RR: 
1.02; 95% CI: 0.71 to 1.48). Pyrexia was more common among women who 
received ~600 Jig rather than 400 Jig of misoprostol (RR: 2.53; 95% CI: 1.78 to 
3.60). 
I have mentioned above that the current widespread use of misoprostol after 
childbirth is based on certain evidence of reduction in the proxy outcome: blood 
loss after birth; and the assumption that reduced blood loss will translate to 
reduced maternal death. One limitation of randomized trials is that they give 
information only on outcomes selected to be measured, and these usually focus 
on the perceived benefits and any known adverse effects of the intervention. In 
the case of misoprostol after childbirth, we focussed on blood loss and the obvious 
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side-effects, shivering and pyrexia. No-one measured other potential side-effects 
such as effects on cardiovascular dynamics, and there are bound to be others 
which have not even been thought of. 
None of the trials have been large enough to assess the risk of death, but of 
course when deaths occurred in the trials, they were recorded. Because the 
intervention aimed to reduce deaths from haemorrhage, there is an intuitive 
(though quite illogical) expectation that if there were an adverse effect on deaths, 
these would also be related to haemorrhage. The idea that misoprostol might 
cause deaths unrelated to haemorrhage is not intuitive, and not easy to accept. 
However, when a death was reported in a trial in Guinea-Bissau in 2005 (Hoj et ai, 
2005), subsequent correspondence in the British Medical Journal pointed out that 
any death in a trial should be regarded as a serious adverse event potentially 
linked to the study drug, and called for a randomized trial of misoprostol with death 
as the end-point ( Sloan Winikoff & Blum, 2005). 
With colleagues, I conducted a systematic review of all randomized trials of 
misoprostol after childbirth, focussing on deaths and effectiveness/side effects in 
relation to dosage (44). Because there were insufficient numbers for robust 
comparison of risk of postpartum haemorrhage from direct comparisons between 
400 and 600 mcg, we used a statistical technique called adjusted indirect 
comparison (Bucher et ai, 1997). In simple terms, randomized trials comparing 
either 400 or 600mcg with a common comparator (injectable oxytocic or placebo) 
were used to extrapolate the relative risks for 400 versus 600 mcg. Both direct 
and adjusted indirect comparisons found no difference in effectiveness between 
the two dosages. We validated the method by applying it to another outcome, 
pyrexia, for which there were much bigger numbers, and therefore robust 
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estimates from the direct comparisons. The indirect method proved to give very 
similar results to the direct method. 
What about adverse effects? With misoprostol 600 mcg about 20% of women 
develop shivering which is severe in 2% of cases, and about 7% develop pyrexia, 
more rarely hyperpyrexia (fever above 40 degrees C, sometimes accompanied by 
delirium). The thermogenic response appears to be geographically related, with a 
rate of hyperpyrexia (>40 degrees C) as high as 36% following misoprostol 800 
mcg sublingually and 16% following 600 mcg sublingually in Ecuador ( Le6n et ai, 
2012). The impact of these side-effects on women have, in my opinion, been 
undervalued, usually by presenting them as a small price to pay for avoiding 
death, for example:. "Although more women in the misoprostol group had 
shivering, in a low-resource setting, this may be acceptable and clearly preferable 
to excessive haemorrhage." (Derman et ai, 2006). However, shivering and 
pyrexia are at the least, unpleasant experiences at a time of intense emotion and 
joy, when a woman wants to focus on her newborn baby. There is good evidence 
that disruption of early mother-child interaction may have long-term harmful 
effects. The discomfort and distress caused by these side-effects alone should be 
reason to avoid the higher dose without good evidence that it is more effective 
than a lower dose. 
This is a classic case of 'where does the burden of proof lie?' Proponents of the 
higher dose want more proof that the lower dose is as effective. My approach is 
that in view of dose-related side-effects, the higher dose should be used only if 
there is proof that it is more effective than the lower dose. 
What about death? To date, among all the randomized trials of misoprostol after 
childbirth involving more than 40 000 women, 15 deaths have been reported. 
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Four of these occurred in the comparison groups (injectable oxytocic or placebo), 
and 11 in the misoprostol groups, all of whom received misoprostol 600 mcg or 
more. This difference is not quite statistically significant. What the figures mean is 
that we can be 95% certain that the true effect of misoprostol in the dosages 
studied on maternal death lies somewhere between a small reduction and a large 
increase. These numbers are too small for certainty, but the balance of probability 
is that in doses of 600mcg or more, the adverse effects of misoprostol on post-
childbirth homoeostatic mechanisms may cause more deaths than are prevented 
by the beneficial effects on uterine contraction. My contention is that even if 
increased death with the higher dose were a remote possibility, this would be a 
compelling reason not to use a higher dose without robust evidence that it is more 
effective than a lower dose. 
I have presented these figures in formal presentations at international meetings in 
Washington and Entebbe (2006), Buenos Aires (2007), Luanda (2008), Seattle 
(2009), and Adelaide (2010), in many expert panel meetings, and we have 
published them in the WHO bulletin in 2009 (40). The figures have never been 
challenged, but they have been comprehensively ignored, and almost never 
quoted. My assumption is that in the context of a global imperative to rollout 
programs routinely using misoprostol 600 mcg after childbirth, the possibility that 
this dosage may cause more deaths than it prevents is too horrifying to 
contemplate. Blocking out that with which we are unable to cope is a human 
survival mechanism, and we are all human. 
My efforts, and those of a few colleagues, to persuade the international health 
community that until we have more evidence, 400 mcg would be a safer dose to 
routinely expose large numbers of women in low-resource setting to, have been 
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spectacularly unsuccessful. Which is why the interchange in the foyer of the 
Fairfax Hotel to which I referred in the introductory interlude to this commentary, 
meant so much to me. One person was listening. 
3.32 Close 
A central theme of this thesis has been the dissonance between my assessment 
of the evidence and balance of possible benefits and harms from misoprostol used 
for specific purposes at specific doses, versus those of the majority of my 
colleagues. I have offered possible explanations for the differences between my 
perspective and that of the majority. I do believe that with time caution will prevail. 
Misoprostol is a unique molecule which probably has the potential to reduce 
maternal mortality worldwide. It also causes many deaths from uterine 
overstimulation and rupture With respect to its use after childbirth, I believe that 
there is a real possibility that the current use of doses above 400mcg may cause 
more deaths than they prevent. From the bottom of my heart, I hope that I am 
wrong. 
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